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To generate a bio-better which has improved therapeutic activity 
than that of hu4D5 (Herceptin), the hu4D5 antibody was used as a 
model system. scFv libraries were constructed by random 
mutagenesis of several resides of CDR-H3, L3 and L2 of hu4D5, 
and the scFv clones isolated from the phage display libraries using 
the “stringent” panning, and their anti-proliferative activity as IgG1 
against breast cancer cells was evaluated as a primary selection 
criterion.  
Among 139 variants variant, AH06 was the best candidate as a 
bio-better antibody that has an increase by 7.2-fold in anti-
proliferative activity (IC50: 0.81 nM) against gastric cancer cell NCI-
N87 and by 7.4-fold in binding affinity (KD: 60 pM) to HER2 
compared to hu4D5, respectively. 
AH06 specifically bound to domain IV of HER2 and did not have 
cross-reactivity with other receptor tyrosine kinases (RTK) except 
HER2, and decreased the level of phosphorylation of HER2 and 
AKT to a similar extent, but most of all, highly increased the overall 
level of p27 in gastric cancer cell NCI-N82 as compared to hu4D5.  
Binding energy calculation indicated that the substitution of 
residues of CDR-H3 to W98, F100c, A101 and L102 could stabilize 
binding of the antibody to HER2. And molecular modeling 
stimulation indicated that the direct hydrophobic interactions 
 ii 
between the aromatic ring of W98 within AH06 and the aliphatic 
group of I613 within antigen HER2 domain IV, and the inter-chain 
hydrophobic interactions between the phenyl ring of F100c in CDR-
H3 and the hydrophobic groups that consist of Y36, P44 and F98 
located in VL could have synergistic effects on improvement in 
binding affinity of AH06 to HER2. 
 
The expression vector for producing AH16 was constructed, and 
the AH16 producing AH16F1-3-14-80-26 clone whose antibody 
growth rate and productivity had been consistently maintained 
during 1~15 passages was finally screened as a stable producer cell 
line. One basal media and 3 additives were selected, and the final 
productivity of AH16 using the optimized media mixture was 
approximately 1.3g/L in flask culture.  
The three chromatography steps using Protein A resin column (1st 
step) and two steps of ion-exchange chromatography provided the 
yield of 93.8% and the purity of 99.9%, and non-Protein A-based 
cation-exchange chromatography provided the yield of 99% and 
the purity of 97.5%.  
Also, analysis of physico-chemical, biological and immunological 
characteristics of AH16 verified that it meets the standards set 
based on the “Specifications and Analytical Procedures”.  
Through this study, the upstream antibody engineering 
technology required to discover and improve biological efficacy of 
various therapeutic lead antibodies and the downstream bioprocess 
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technology required to produce antibody were able to be 
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1.1 Research Backgrounds 
 
Antibody seems to be ideal molecule as targeting reagent by 
binding with high specificity and affinity to a wide variety of 
molecules, and therefore, widely used in research, diagnosis and 
treatment for disease. In particular, the engineered antibody has 
been used as a disease-curing agent in clinical fields via 
neutralizing disease-inducing target antigen or regulating cellular 
function of target cells expressing the disease-related specific 
antigens.  
It is possible to develop human antibodies designed to increase 
efficacy, to reduce side effects, and to increase productivity of the 
antibody in a variety of diseases such as cancer, immunological 
disease, infective disease and metabolic diseases. The reasons why 
the antibody has been widely used for curing various diseases are 
that it is a natural product of humans with low toxicity and high 
safety, and its stability and specificity are relatively superior to 
those of small molecule drugs in human body (Imai and Takaoka, 
2006).    
Various target antigens have been studied for the development of 
therapeutic antibodies used for curing cancer and immunological 
diseases. One of the antigens is HER2 protein over- expressed on 
the breast and gastric cancer cells. 
 
HER2 is a receptor tyrosine kinase located in cell membrane and a 
 3 
member of the ErbB/HER (Human epidermal growth factor 
receptor) family that consists of EGFR, HER2, HER3 and HER4. 
HER2 has been implicated important roles in growth, 
differentiation and survival in cancer cells as well as in normal cells 
(Whenham et al., 2008). In contrast to other HER family members, 
HER2 does not require ligands for the receptor-receptor 
interactions (Nicolas et al., 2008). In cancer cells, the HER2 protein 
can be expressed up to 100 times more than in normal cells (2 
million versus 20,000 per cell, respectively) (Shepard et al., 1991). 
Such overexpression or amplification of HER2 promotes the 
formation of receptor homo- and heterodimers with other HER 
family members, leading to uncontrolled cell proliferation and 
tumor growth (Mayumi et al., 2006). 
Therefore, HER2 has been investigated as a promising therapeutic 
target for cancer. Particularly, targeted-therapy using anti-HER2 
monoclonal antibodies such as Herceptin (Trastuzumab, hu4D5: 
binding to domain IV), Kadcyla (Trastuzumab-maytensinoid: 
antibody-drug conjugate) and Perjeta (Pertuzumab: binding to 
domain II) has been used to treat HER2 positive cancers.  
 
Herceptin (trastuzumab) launched by Genentech in October 1998 
is a humanized version of murine monoclonal antibody, hu4D5. It 
binds extracellular domain (ECD) IV of HER2 receptor, 
subsequently inhibits its downstream PI3K-Akt signaling (Hudziak 
et al., 1989; Yakes et al., 2002; Sliwkowski et al., 1999) and induces 
 4 
cell cycle arrest via induction of cyclin-dependent kinase inhibitor 
p27/kip1 and apoptosis (Carter et al., 1992) in metastatic HER2 
positive breast and gastric cancer cells, which in turn inhibits 
HER2-meidated tumor growth.  
A combination of Herceptin with chemotherapy has shown 
significant improvements in cancer treatment. Disease-free 
survivals were 75.4% and 87.1% with chemotherapy alone and in 
combination with Herceptin, respectively, in patients with HER2-
overexpressing metastatic breast cancer (Romond et al., 2005). 
However, despite its proven clinical benefit, most patients who 
have an initial response to Herceptin develop resistance within one 
year of treatment initiation. 
Accordingly, it is required to develop another anti-HER2 antibody 
having improved affinity, efficacy or the like. For this purpose, 
various approaches are as follows: screening a novel anti-HER2 
antibody with different epitope, random mutagenesis strategies of 
Herceptin (hu4D5) variable region or Fc-engineering technologies 
enhancing antibody effector function (e.g., antibody dependent 
cell–mediated cytotoxicity, ADCC) by increasing its binding to 
FcIII on effector cells such as macrophages.  
For this purpose, a strategy to improve the binding affinity and 
efficacy of the antibody is mutagenesis, and particularly 
substitution of the residues at some positions of CDR-H and CDR-L 
would be considered. Based on this way, it was previously 
reported that substitution of residues in the CDRs of hu4D5 
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influences antibody affinity (Gerstner et al., 2002). 
 
In the previous report, Gerstner et al. constructed phage-displayed 
Fab libraries targeting 19 positions of hu4D5 (Gerstner et al., 2002) 
including R50(VH), W95(VH), Y100a(VH) and H91(VL) known to be 
important to bind with HER2 molecule (Kelley et al., 1993). The 
libraries were divided into five groups by 5~7 residues, 
respectively. The binding affinity of a single mutant D98 (VH)W (KD 
0.11 nM) was increased by 3-fold compared to the parent antibody 
hu4D5, but the anti-cancer activity of the variant was not reported. 
They also suggested that further improvement in binding affinity 
could be found using alternative methods of binding selection or 
targeting more plastic or variable positions (Gerstner et al., 2002). 
However, there were no reports of success in screening variants 
superior to D98(VH)W in binding affinity and functional activity 
such as anti-cancer activity until now. 
 
Therefore, screening was carried out using Herceptin as a 
template antibody to discover the biobetter antibody with 
improved activity and bioprocess study was performed for the 






1.2 Research Objectives 
 
The aim of our study was to investigate whether further 
modifications of the antibody that has been already affinity-
maturated could improve its binding affinity and subsequent 
biological activity or efficacy, and to establish antibody 
optimization technology for antibody improvement strategy, using 
hu4D5 as a model system. Also, it was aimed to set up a series of 
bioprocess technologies required to produce the selected antibody, 
and to apply the bioprocess platform technologies to discover and 
develop new antibody therapeutics.  
 
Firstly, the CDR regions of Herceptin that already has high 
binding affinity to specific antigen HER2 were changed by random 
mutagenesis, and the following screen was planned to select the 
variants with improved anti-cancer activity and binding affinity. In 
addition, since there was a possibility to increase those activities by 
mutating the framework part (or region) instead CDR regions 
(Ding et al., 2010; Kobayashi et al., 2010), it was aimed to select new 
improved HER2-targeting therapeutic antibodies through error-
prone random mutagenesis of the entire variable region from the 
selected variants and the well-established phage display 
technology.  
 
Secondly, in vitro functional anti-tumor activity, binding affinity, 
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target cross-reactivity (specificity), mechanism of signaling 
inhibition and in vivo anti-tumor activity of variants were evaluated, 
and, it was also speculated how to attribute the modification of 
hu4D5 to improvement in binding affinity using molecular 
modeling analysis. 
 
In addition, to produce and supply the selected antibody samples 
required to proceed development process for clinical trials and 
launch, the following bioprocess has progressed. 
 
Thirdly, to produce the stable cell line producing a large amount 
of the selected antibody, the study on screening of high-producing 
stable cell line was conducted. By screening, the stable cell line with 
high-producing and stable growth was selected, and was used to 
perform the following study for optimization of antibody 
production.  
 
Fourthly, the screening of basal media and additives for 
improving growth, survival rate and the antibody productivity of 
the selected stable cell line and the optimization of purification 
process for the purpose of establishing antibody separation and 
refining methods were performed. 
 
Fifthly, in this way, the “Specifications and Analytical 
Procedures” for the biobetter antibody was established by 
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evaluating the physical-chemical and biological characteristics of 
the highly purified final antibody produced through the validated 
bioprocess. In addition, feasibility and robustness of the validated 
bioprocess were determined by evaluating the quality of antibody 
produced through the bioprocess. 
 
Distinctively, in this study, mutagenesis was performed on CDR 
residues affecting the heavy and light inter-chain interaction as well 
as CDR resides participating in binding to the antigen unlike 
Gerstner et al. carried out only the latter strategy (Gerstner et al., 
2002). Another distinctive point is that the sublibrary construction 
and combinatorial expression by mutagenesis of each heavy and 
light CDR instead of mutagenesis of heavy and light CDRs in one 
scFv library, which can reduce the enormous size of library 
construction . 
 
Therefore, the objectives of this work are summarized as follows. 
 
 To screen and discover improved antibody variants by 
random mutagenesis and phage display technology using 
CDR and FR region of Herceptin as a template 
 
 To evaluate biological activities of the isolated variants and 
to analyze the improved binding affinity using molecular 
modeling analysis (simulation) 
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 To produce the stable cell line, screen basal media & 
additives, set up process for antibody purification, and 





































2.1 Clinical needs of therapeutic antibody 
 
 Antibody seems to be ideal molecule as targeting reagent by 
binding with high specificity and affinity to a wide variety of 
molecules, and therefore, widely used in research, diagnosis and 
treatment for disease. Studies in genomes and proteome have made 
it possible to identify a wide variety of molecules as therapeutic 
targets.  
In vertebrate, immune system can produce antibodies that have 
high affinity for any kinds of antigen based on genetic diversity. 
Recently, therapeutic monoclonal antibodies are emerging as the 
therapeutic agent for the wide range of diseases including cancer, 
autoimmune and infectious diseases. 
By using the technologies of developing therapeutic antibody such 
as humanization and optimization of antibody, it is possible to 
develop human antibodies designed to increase efficacy, to reduce 
side effects, and to increase productivity of the antibody in a 
variety of diseases such as cancer, immunological disease, infective 
disease and metabolic diseases. Now, monoclonal antibodies used 
for therapeutic and diagnostic reagents for a long time are now 
emerging as a major biologics following chemical drug. 
Since the clinical importance and industry of therapeutic antibody 
have continuously increased, many pharmaceuticals and bio-
ventures worldwide have invested to develop novel monoclonal 
therapeutic antibodies and technologies. And the therapeutic 
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monoclonal antibody is expected to lead the market as the next 
generation of antibody-based therapeutic agents. Consequently, 
following this trend, more than 30 therapeutic antibodies were 
developed (Table 2-1) (Janice, 2012) in year 2012, and currently, 
over 1,000 antibodies are being discovered and developed. 
 
Table 2-1. Therapeutic monoclonal antibodies marketed or in 
review in the European Union or United States in March 2012 
(Janice, 2012).  
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2.2 Types of therapeutic antibody 
 
2.2.1 Mouse antibody 
 
In 1975, a murine monoclonal antibody, which is produced from 
‘hybridoma’ technique invented by Kohler and Milstein in Britain 
(Köhler and Milstein, 1992), has high selectivity and specific 
binding affinity. Therefore, it has been used for various fields 
efficiently. Especially, because monoclonal antibody can target 
variety antigens and be produced for large-scale, it is widely used 
for clinical diagnosis and research agents (Fuchs et al., 1992; Vieira 
and Messing, 1987). Currently, there are six mouse antibodies 
approved for the treatment of diseases.  
 
However, the application of murine monoclonal antibodies for 
therapy has raised several problems. One major drawback is, for 
instance, that mouse Abs are recognized as antigen in human and 
can induce the formation of a human anti-mouse antibody 
(HAMA) response after repeated injection. It causes the low 
response rate for efficacy of therapy. To solve these problems, a 
humanized antibody such as Herceptin was designed and 





2.2.2 Chimeric antibody 
 
In order to reduce the HAMA response, a technique of replacing 
the constant region of a mouse antibody with a constant region of a 
human antibody has been developed. Chimeric antibody contains 
approximately 65% human sequences. It may significantly decrease 
the HAMA response but still have immunogenicity due to the 
mouse Fv sequences. Rituximab (Reff et al., 1994) and Remicade 
(infliximab) (Knight et al., 1993; Scallon et al., 1995) are examples of 
the typical chimeric antibodies approved for lymphomas and 
rheumatoid arthritis, respectively. 
 
 
2.2.3 Humanized antibody 
 
Antibody can be divided into variable and constant regions, and 
the variable region consists of CDR (complementarity determining 
region) which directly binds to the specific antigen and FR 
(framework region) which supports the structure of CDR loop 
(Marchalonis et al., 2006). The humanized antibodies such as 
Herceptin are made using CDR grafting technology that the CDR 
loops of mouse antibody is grafted into FR of human antibody 
(Kettleborough et al., 1991).  
Since the humanized antibodies contain about 5~10% of mouse 
antibody sequences and have less HAMA (human anti-mouse 
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antibody) response than the mouse antibodies, they may have 
better efficacy than the mouse antibodies. And since the 
productivity and thermodynamic stability of Herceptin is relatively 
high, and the immunogenicity of Herceptin is very low as about 
0.5%, the framework region of Herceptin is sometimes used as a 
template for generating the humanized antibody (Carter et al., 
1992). 
Humanized antibodies are produced by grafting hypervariable 
regions of a murine antibody onto the human antibody framework. 
As compared to murine and chimeric antibodies, it greatly reduces 
immunogenicity increases a half-life in vivo. However, the affinity 
of the humanized antibody is decreased in the process of the CDR 
grafting. In this case, it could be solved by re-introducing the 
murine framework residues that play an important role in the 
structure of the CDR or the affinity maturation.    
Herceptin (trastuzumab) (Carter et al., 1992) is a representative 
humanized antibody approved for breast cancer therapy. 
 
 
2.2.4 Fully human antibody 
 
Although humanized antibodies comprise murine sequence to less 
than 10%, they might still be immunogenic. Thus, researchers have 
tried to develop a fully human antibody by using transgenic mice 
or display technologies.  
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Advances in techniques for the manipulation of the germline of 
mammalian embryos led to the creation of transgenic mice 
technology. These mice directly generate high affinity human 
sequence antibodies de novo in response to immunization. Vectibix 
(panitumumab) is the first antibody developed by immunization of 
transgenic mice that produce the human immunoglobulin light and 
heavy chains (Yang et al., 2001). More fully human antibodies will 
be developed using this technology.  
 
 
2.3 Antibody engineering technology  
 
2.3.1 Phage display technology and its application  
 
Besides human hybridoma technique, human mAb has recently 
been produced using two skills, ‘Phage display’ and ‘Transgenic 
Mice’. Particularly, the technology of Phage Display is a typical 
technique to reproduce the discovery of antibody in test-tube scale 
(Pasqualini and Ruoslahti, 1996; Cheng et al., 2005). 
The phage display has many advantages. It can produce antibody 
fragments such as scFv and Fab in bacterial hosts such as E. coli in 
quantity, more efficiently, quickly and at a lower cost, compared to 
production of whole antibody. And these fragment antibodies 
induce less immune responses than murine mAb and have better 
penetration into tumor tissue than whole IgG (Farajnia et al., 2014). 
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In the mid-1980s, George P. Smith invented the cell surface-
expression system in which peptides or small proteins are fused to 
pIII of a filamentous phage. Since then, the research on the 
secretion mechanism of microorganisms was actively progressed, 
and a new field called “Cell Surface Display“ that expresses target 
proteins on the surface of microorganisms, was appeared (Rader et 
al., 1998; Baca et al., 1997).  
Cell surface display is a technique that a foreign target protein is 
stably expressed on the surface of microorganism such as bacteria 
and yeast through fusion with the surface anchoring motif. Using 
ssDNA of filamentous phage, a foreign antigen fused to the coat 
protein is expressed in host bacteria cells, and then the foreign 
protein is expressed through the replication system of a helper 
phage and the phage coat protein (Rader et al., 1998; Baca et al., 
1997). This process is called phage display (Fig. 2-1). 
 
Phage display technique is used to express antibody library that 
has high diversity through genetic recombination on the surface of 
bacteriophage. Because a specific antibody for antigen is easily 
isolated and amplified using this skill, it is a very important tool for 
antibody engineering. (Clackson et al., 1991; Hoogenboom and 
Chames, 2000; Hoet et al., 2005). Phage display makes antibody 
discovery more efficient and takes less time. Especially, human 
antibody for development of new therapeutic antibody can be 
produced by this skill; phage display is widely exploited in the 
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Fig. 2-1. The method of panning using recombinant phage 
displayed library.  
(Source from http://axiomxlab.wpengine.com)  
 
 
Phage display technology first developed by British Medical 
Research Council in 1990s is a technique that peptide, particularly 
the antibody fragment such as Fab and scFv, is fused with the coat 
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protein of bacteriophage and expressed on surface of phage. These 
proteins organize phage antibody library. A phage clone, which has 
peptide or antibody fragment specific to particular antigen, is 
selected by phage library. (Parsons et al., 1996; Barbas et al., 2004) 
 
Phage display is a fundamental technology showing superior 
selection power among biotechnologies developed until now. 
(Giordano et al., 2001; Yang et al., 1999; Krebs et al., 2001; Dower et 
al., 1988) (Fig. 2-4). However, it is possible for the selected human 
antibody to have low affinity. (Knappik et al., 1995; Krebber et al., 
1996; Azzazy et al., 2002; Baek et al., 2004; Corisdeo et al., 2004). In 
this case, it is necessary to perform affinity maturation.  
In this phage display, a skill called ‘panning’ is needed to select 
the protein that specifically binds to the target antigen among 
recombinant phage library expressing recombinant fusion pIII with 
various sequence (Rader et al., 1998; Baca et al., 1997) (Fig. 2-1). 
 
 
2.3.2 Phage display technology: system requirements  
 
The phage display system is composed with 1) phage vector 
system using bacteriophage genome as a cloning vector, and 2) 
phagemid vector system using phagemid vector, a fusion type of 
phage genome and plasmid. The vector mentioned above is 
recombined with specific peptide or foreign protein through 
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genetic cloning, and then target protein is successfully exposed 
(displayed) on the surface of phage as fusion to phage-coated 
protein, p3 or p8.  
In case of displaying foreign protein such as antibody, the 
phagemid vector system can be utilized. Unlike peptide display 
with phage genome, phagemid has only part of phage genome, and 
there is no gene for replication, assembly of real type bacteriophage 
and coat protein in phagemid. Thus, phagemid vector cannot 
produce new phage particles by itself.  
 
In phagemid vector system, a helper phage needs to be added for 
replication, assembly of a recombinant phage and production of 
coat protein, this process is called phage rescue. On the surface of 
the recombinant phage obtained through the phage rescue, there 
are not only fusion-pIII, the fusion protein of antibody and phage 
coat protein p3, but also a lot of wild type pIIIs. This problem 
makes numerous technical difficulties in selection of recombinant 
phage targeting specific antigen from phage library. To solve these 
problem, various types of helper phage (Ex-phage, CT-phage, 
hyper-phage, VCS M13, Phaberge, etc) have been developed and 
utilized (Steiner et al., 2006).  
 
From the ‘phage display library’ that is a complex of recombinant 
phage particle expressing random peptide or various foreign 
protein, a recombinant phage fused peptide or protein specific 
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binding to target protein or ligand is selected and acquired by 
searching method called ‘bio-panning’ (Fig. 2-1). The isolated 
recombinant phage has a phenotype-genotype linkage between 
gene in phagemid genome and target-specific peptide or protein 
expressed on the surface of phage. Thus, genetic information of 
target peptide or protein can be confirmed (Rowley et al., 2004). 
 
 
2.3.3 Yeast display 
 
Yeast surface display technology was reported by Boder and 
Wittrup in 1997 (Boder and Wittrup, 1997). This technique has 
become a powerful tool for protein engineering and library 
screening. The principle of this technique is to use a yeast mating 
adhesion receptor -agglutinin (Aga) that is a glycoprotein 
composed of two subunits, Aga1p and Aga2p. Aga serves to 
anchor recombinant proteins to the cell surface. Aga1p is an 
anchoring subunit tethered to the yeast cell wall via a -glucan 
covalent linkage at its carboxyl terminus and Aga2p is an adhesion 
subunit covalently linked to Aga1p by two disulfide bonds (Zou et 
al., 2000). 
 
The use of an eukaryotic host provides the significant advantage 
in posttranslational processing and modification of proteins of 
animal origin. Also, it allows the quantitative analysis in 
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conjunction with FACS cytometry and thus enables efficient 
screening for proteins having a high affinity. However, it is difficult 
to produce a large size library due to the limited yeast transformation 
efficiency (Benatuil et al., 2010).  
 
 
2.3.4. Ribosome display 
 
Ribosome display reported by Hanes and Plückthun in 1997 
(Hanes and Plückthun, 1997) is a powerful in vitro technology for 
screening proteins. It is a method for selecting a proteins 
specifically binding to a target using a cell-free translation system. 
 
The mRNA library is generated by in vitro transcription from a 
cDNA library produced by PCR. After in vitro translation, a stable 
ribosomal complex is achieved as a result of coupling the 
phenotype and genotype. After the selection process, the mRNA–
protein complexes are then reverse-transcribed to cDNA and their 
sequences are amplified using PCR. After repeating this process, it 
is possible to obtain the sequence of the protein binding to the 
target antigen. 
 
Ribosome display has two advantages. First, the large size library 
whose diversity is not limited can be made quickly and easily. 
Second, additional mutations can be introduced easily.  
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2.3.5. Humanization of mouse antibody 
 
Antibody humanization technology is the representative 
technique to reduce the immunogenicity of the mouse antibodies. 
When a mouse antibody administered to a human, HAMA (human 
anti-mouse antibody) response is induced. The HAMA response 
influences the safety, efficacy and half-life of the antibody (Khazaeli 
et al., 1994).  
 
There are two common techniques for antibody humanization. 
One is chimerization, replacement of the constant region of a 
mouse antibody with that of a human antibody (Boulianne et al., 
1994; Morrison et al., 1984; Neuberger et al., 1984). HAMA response 
of some mouse antibodies is reduced through chimerization.  
 
However, other antibodies may still have immunogenicity due to 
sequences of the mouse Fv. Thus, Jones et al. reported the 
technology to implant the CDR regions of a mouse antibody onto 
the Fv framework of a human antibody (Jones et al., 1986; 
Riechmann et al., 1988; Verhoeyen et al., 1988). Immunogenicity of 
the humanized antibody is minimized by using only the sequence 





2.3.6 Fc engineering 
 
Antibodies can act on other cells or proteins and induce various 
biological activity, such as ADCC (antibody dependent cell 
cytotoxicity) and CDC (Complement dependent cytotoxicity), 
which is referred to as antibody effector functions (Strohl, 2009). 
Effector function of the antibody is derived by the Fc region of the 
antibody heavy chain. A receptor capable of reacting with the Fc 
region of an antibody is called the Fc receptor. The Fc gamma, Fc 
epsilon and Fc alpha receptors bind IgG, IgE and IgA, respectively. 
Antibodies reacting with the Fc receptors induce effector functions 
such as ADCC (antibody dependent cell cytotoxicity) and CDC 
(Complement dependent cytotoxicity) responses (Daëron, 1997). 
Thus, Fc engineering technology to control ADCC, CDC and the 
half-lives of antibodies has been developed. 
 
Lazar et al. described a triple mutant (S239D/I332E/A330L) with 
a higher affinity for FcγRIIIa and a lower affinity for FcγRIIb 
resulting in with enhanced ADCC (Lazar et al., 2006; Ryan et al., 
2007). Notably, alanine substitution at position 333 was reported to 
increase both ADCC and CDC (Presta et al., 2000; Idusogie et al., 
2001). It has been shown that an increase in the binding affinity of 
the antibody to FcRn leads to an increase in the half-life of IgG1 in 
vivo (Hinton et al., 2004; Vaccaro et al., 2005).   
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2.4. Bioprocess development technology 
 
2.4.1 Development of stable cell line 
 
The dihydrofolate reductase (dhfr) (Urlaub et al., 1983; Kaufman 
et al., 1985; Werner et al., 1998) expression system or glutamine 
synthetase (GS) system (Wurm, 2004; Birch and Racher, 2006; 
Cockett et al., 1990) are widely used for development of stable cell 
lines with high productivity. Cells are transfected with a construct 
containing a selectable marker and subjected to selection. After 
screening the highly productive stable clones, bioprocesses are 
further developed and optimized for large-scale production.  
DHFR is an amplifiable and selectable marker, so routinely use to 
establish cell lines. The parental CHO cell was mutagenized to 
yield DG44, a cell line with deletion of DHFR. DG44 was adapted 
for the large-scale suspension culture (Trill et al., 1995). DHFR 
converts 5, 6-dihydrofolate into 5, 6, 7, 8-dihydrofolate, which is 
required for the de novo synthesis of nucleic acid precursors, such 
as purine. This purine plays central role in cell division and 
maintenance of cell survival through DNA replication after 
synthesizing nucleic acids (Hamlin, 1992).  
Purine precursors, hypoxathine and thymidine (HT) are therefore 
necessary for growth and survival of DHFR-deficient DG44 cells. If 
the construct containing DHFR and a target gene is stably 
integrated into the chromosome of DG44 cells by transfection, the 
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transfected cells can survive in the media without HT.  
DHFR also functions as a genetic marker for amplification of a 
target gene using MTX (methotrexate) selection. If MTX is present 
in the media, the cells amplify DHFR gene copy number in the 
genome to overcome inhibition by MTX. Since the target gene is 
integrated into the same locus as DHFR gene, it can also be 
amplified, leading to an increase in expression of the target protein 
(Gu et al., 1992; Ng, 2012).  
 
 
2.4.2 Optimization of cultivation media and additives 
 
Basic carbon source (sugar), energy source (glucose), nitrogen 
source (amino acids), inorganic salts, trace elements, vitamins, 
growth factors and buffering agents should be included in the 
culture media used in the cultivation of the antibody-producing 
cells such as mammalian animal CHO DG44 cells (Kim et al., 1999; 
Parampalli et al., 2007). In addition, 5~20% of serum could be 
added.  
Animal serum has been generally used in cell culture media, but 
since then the recombinant protein drugs was accidently produced 
in animals cell cultures, using the serum was gradually became to 
be removed due to the trend in biopharmaceutical approvals to 
remove unknown (or uncertified) constituents and risk of infection 
of the animal-origin ingredients (Butler, 2005).  
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In addition, the serum is expensive and the separation and 
refining process of the products from cell culture is very 
complicated due to proteins and peptides within the serum. Since 
the sterilization method of serum is not heat sterilization but only 
filtration, there is an increasing possibility of mycoplasmas or virus 
contamination. And since the composition of serum varies 
considerably in quality from batch to batch, it is difficult to obtain 
the reproducibility of experiments (Witzeneder et al., 2005).  
Therefore, in order to overcome these issues, the research to find 
which element is suitable to replace a serum (Mariani et al., 1991; 
Barnes and Sato, 1991), in other words, the study on the media 
development regarding the required ingredients and their 
combination has been developed.  
In addition to glucose, glutamine, amino acids and salts, insulin, 
transferrin and selenium could be used in serum-free media to 
replace serum (Iscove and Melchers, 1978; Parampalli et al., 1978). 
And since the components composition of the serum-free media is 
clearly known and defined, it is easy to standardize the media 
composition, to give high-reproducibility of the experiment, to 
easily sterilize and to purify the products.  
However, there are problems in the use of serum-free media: the 
cost of media is expensive if specific hormones or growth factors 
needs to be added; the rate of cell growth is slower than the serum 
containing media; it should be a personalized production 
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depending on the intended use; different cell lines requires the 
different media composition (Grillberger et al., 2009).  
Therefore, it needs to study on screening of serum-free media 
additives to complement the disadvantage of the media and to 




2.4.3 Optimization of antibody purification process: Protein A 
and non-Protein A process 
 
Protein A column is an affinity chromatography column based on 
an interaction between protein A and immunoglobulin G 
(Jendeberg et al., 1996). Protein A column may need to be carefully 
selected because it is expensive as well as has a significant impact 
on the efficiency of the process. Therefore, selecting the appropriate 
protein A resin is a critical step in development of purification 
process based on Protein A affinity chromatography (Shukla et al., 
2007; Liu et al., 2010; Kelley, 2009; Moser and Hage, 2011). And 
ligand leaching should be considered as a key factor for resin 
selection because it affects purity of purified product, capacity and 
life cycle of column (Carter-Franklin et al., 2007).  
Antibody purification process can be divided into Protein A-based 
purification and non-Protein A-based purification processes, 
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depending on the use of Protein A resin. A Protein A-based 
purification step is only having the advantage of being able to 
purify the antibody in high purity, high efficiency, but its cost of 
the resin is expensive (Kent, 1999; Fahrner et al., 2001; Marichal-
Gallardo and Alvarez, 2012), and ligand leaching could be a 
possible problem.  
 
Non-Protein A process can be established at lower costs than 
Protein A process and does not require monitoring leached protein 
A. In addition, new specialized resins that and enable efficient 
antibody purification with high purity have been developed. 
Therefore, it is worth developing non-Protein A-based purification 
processes.  
 Cation exchange chromatography is based on the principle that it 
holds on positive electric charged molecules and flows negative 
electric charge. Isoelectric point of IgG is known about 6.1 ~ 8.5 
(Bumbaca et al., 2012). Therefore, antibodies are positively charged 
at the pH of neutral or below and can be separated by cation 
exchange chromatography. 
For example, the material with a pI value of 9 is positively charged 
in the neutral buffer solution and it means that it interacts with 
cation exchanger. Protein is in folded state, so its surface charge is 
more important than the net charge. However, it is general to refer 
to the theoretical pI in cation exchange chromatography initial try.  
In general, non-protein A capturing process is known to be 
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slightly inferior to Protein A process in terms of the yield and 
purity, but Non-protein A-based process has the advantages: there 
is no need to keep track of the leached Protein A toxicity and it is 
cheaper than Protein A process in production cost. 
 
 
2.5 HER2 as a therapeutic target of anticancer antibody 
 
2.5.1 Biological functions of HER2 on cancer  
 
One of the representative features that appear in many species of 
cancer is deregulation such as over-expression of tyrosine kinases 
(RTKs). HER2 (also known as Neu or ErbB2), a receptor tyrosine 
kinase that belongs to the human epidermal growth factor receptor 
(EGFR) family including HER1 (ErbB1/EGFR), HER3 (ErbB3) and 
HER4 (ErbB4) (Calogero et al., 2007), exists on the normal and 
cancer cell membranes and plays an important role in cell growth, 
differentiation and survivals (Fig. 2-2). Over-expression of HER2 on 
the cancer cells induces homodimerization as well as 
heterodimerization with other family members such as HER1 and 
HER3, which initiates a variety of signaling pathways and 




















The unique feature of HER2, which differentiates HER2 from the 
other members of the family, is the absence of a known ligand. Its 
activity is subsequent to homo- or hetero dimerization with the 
other family members. Breast cancers can have up to 25~50 copies 
of the HER2 gene and up to 40~100 fold increase in HER2 protein 
expression resulting in up to 2 million receptors expressed at the 
tumor cell surface (Shepard et al., 1991). 
In particular, overexpression of HER2 has been reported in about 
20~30% of invasive breast cancer patients and in other forms of 
cancers such as ovary (15~30%), stomach (23%), Lung (11~32%), 
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kidney (30~40%), colon (17-90%), pancreas (26~45%), bladder (44%), 
prostate (12%) and head and neck (29~39%). (Baxevanis et al., 2004; 
Swanton et al., 2006; Mineo et al., 2004; Lara et al., 2002; Høgdall et 
al., 2003; Matsui et al., 2005; Lei et al., 1995; Seliger et al., 2000; 
Ménard et al., 2001; Bei et al., 2004). Therefore, HER2 is a promising 
therapeutic target for cancer drug discovery. 
 
HER2 has no known direct activating ligand and may be in an 
activated state constitutively or become active upon 
heterodimerization with other family members such as HER1 and 
HER3. The HER2 receptor has an important role in normal cell 
growth and differentiation. However, overexpression of the HER2 
promotes the formation of HER2 heterodimerization, which leads 
to more aggressive tumor growth (Davoli et al., 2010). Because of 
the oncogenic pathway of HER2, a number of monoclonal 
antibodies such as Herceptin or Perjeta directed against the HER2 
receptor have been actively developed. 
 
 
2.6. Needs for new anti-HER2 antibody 
 
Herceptin (Trastuzumab, hu4D5 : humanized version of 4D5, 
Genentech) was approved as part of a treatment regimen 
containing doxorubicin, cyclophosphamide and paclitaxel for the 
adjuvant treatment of women with node-positive, HER2 
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overexpressing breast cancer in 1998. Herceptin selectively blocks 
HER2-HER2 dimerization through binding to domain IV of the 
extracellular segment of the HER2 receptor and subsequently 
inhibits tumor growth (Molina et al., 2001) (Fig. 2-2). In addition, 
Herceptin binding to HER2 blocks proteolytic cleavage of the 
extracellular domain of HER2, resulting in diminished levels of the 
more active p95-HER2 form of HER2. However, Herceptin did not 
suppress tumor growth completely by failing to disrupt HER2-












Fig. 2-3. Action mechanism of Herceptin (Trastuzumab) and 





Herceptin is indicated for HER2-overexpressing metastatic breast 
cancer and adjuvant treatment of HER2 overexpressing node 
positive or node negative breast cancer. The objective response 
rates of Herceptin with cytotoxic drug range from 38 to 50%. 
However, the objective response rates to Herceptin monotherapy 
range from 12 to 34% and acquired resistance to Herceptin has been 
increasingly recognized as a major obstacle in the clinical 
management of this disease. In addition, incidence of congestive 
heart failure was 2~7% in women with Herceptin monotherapy and 
11~28% in women with Herceptin plus chemotherapy. One in 10 
women could not receive Herceptin due to the risk of heart failure 
(Hudis et al., 2007).  
Sporadic cases of congestive heart failure were reported in major 
side effects of Herceptin. A total of 27% of patients treated 
concurrently with Herceptin and anthracyclines, 13% with 
Herceptin and paclitaxel, and 5% with Herceptin alone experienced 
cardiotoxic effects (Hudis et al., 2007). 
 
Despite benefits of Herceptin in adjuvant and neoadjuvant uses, 
its efficacy was not perfect. Several issues are under investigation, 
including cardiac safety, the optimal treatment duration, the benefit 
of treatment after disease progression, combinations with 
additional anti-HER2 targeting agents, and health care costs. 
Therefore, the community needs to develop another anti-HER2 
antibody with improved efficacy and reduced cardiac toxicity risk. 
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Therefore, HER2-overexpressing breast cancer led to development 
of another HER2 targeted antibodies. Perjeta (Pertuzumab, 
Omnitarg, Genentech), a new anti-HER2 antibody, has been 
approved in 2013 by the European Medicine Agency.  
 
Pertuzumab, a monoclonal antibody directed against a portion of 
the extracellular domain II of HER2, sterically blocks the ability of 
HER2 to heterodimerize with other members of the family and 
induces apoptosis and cancer cell death (Fig. 2-2). Clinical efficacy 
of Pertuzumab was reported to be low when used alone but very 
striking when used in combination with Herceptin. Therefore, 
Perjeta is used only in combination with Herceptin for the 
treatment of HER2-overexpressing metastatic breast cancer patients 
(Franklin et al., 2004). Therefore, it still needs to develop another 














HER2 Antibody Improvements using  
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HER2 is a member of the ErbB/HER (Human epidermal growth 
factor receptor) family which consists of EGFR, HER2, HER3 and 
HER4. HER2 has been implicated important roles in growth, 
differentiation and survival in cancer cells as well as in normal cells 
(Whenham et al., 2008). In contrast to other HER family members, 
HER2 does not require ligands for the receptor-receptor 
interactions (Nicolas et al., 2008). In cancer cells the HER2 protein 
can be expressed up to 100 times more than in normal cells (2 
million versus 20,000 per cell, respectively) (Shepard et al., 1991). 
Such overexpression or amplification of HER2 promotes the 
formation of receptor homo- and heterodimers with other HER 
family members, leading to uncontrolled cell proliferation and 
tumor growth (Mayumi et al., 2006; Ono and Kuwano, 2006).  
 
HER2 is a member of the ErbB/HER (human epidermal growth 
factor receptor) family which consists of EGFR, HER2, HER3 and 
HER4. HER2 has been implicated important roles in growth, 
differentiation and survival in cancer cells as well as in normal cells 
(Whenham et al., 2008). 
Therefore, HER2 has been investigated as a promising therapeutic 
target for cancer. Particularly, targeted-therapy using anti-HER2 
monoclonal antibodies such as Herceptin (Trastuzumab, hu4D5: 
binding to domain IV), Kadcyla (Trastuzumab-maytensinoid: 
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antibody-drug conjugate) and Perjeta (Pertuzumab: binding to 
domain II) has been used to treat HER2 positive cancers.  
 
Herceptin (trastuzumab) launched by Genentech in October 1998 
is a humanized version of murine monoclonal antibody, hu4D5. It 
binds extracellular domain (ECD) IV of HER2 receptor, 
subsequently inhibits its downstream PI3K-Akt signaling (Hudziak 
et al., 1989; Yakes et al., 2002; Sliwkowski et al., 1999) and induces 
cell cycle arrest via induction of cyclin-dependent kinase inhibitor 
p27/kip1 and apoptosis (Carter et al., 1992) in metastatic HER2 
positive breast and gastric cancer cells, which in turn inhibits 
HER2-meidated tumor growth.  
A combination of Herceptin with chemotherapy has shown 
significant improvements in cancer treatment. Disease-free 
survivals at 3 years were 75.4% and 87.1% with chemotherapy 
alone and in combination with Herceptin, respectively, in patients 
with HER2-overexpressing metastatic breast cancer (Romond et al., 
2005). However, despite its proven clinical benefit, most patients 
who have an initial response to Herceptin develop resistance 
within one year of treatment initiation. 
Accordingly, it is required to develop another anti-HER2 antibody 
having improved affinity, efficacy or the like. For this purpose, 
various approaches are as follows: screening a novel anti-HER2 
antibody with unknown epitope, random mutagenesis strategies of 
Herceptin (hu4D5) variable region or Fc-engineering technologies 
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enhancing antibody effector function (e.g., antibody dependent 
cell–mediated cytotoxicity, ADCC) by increasing its binding to 
FcIII on effector cells such as macrophages.  
Among these approaches, for this purpose a popular strategy to 
improve the binding affinity and efficacy of the antibody is 
mutagenesis, and particularly, substitution of the residues at some 
positions of CDR-H and CDR-L would be considered. Based on this 
way, it is previously reported that substitution of residues in the 
CDRs of hu4D5 influences antibody affinity (Gerstner et al., 2002). 
 
In the previous report, they constructed phage-displayed Fab 
libraries targeting 19 positions of hu4D5 including R50(VH), 
W95(VH), Y100a(VH) and H91(VL) known to be important to bind 
with HER2 molecule (Kelley et al., 1993) (Fig. 3-1). The libraries 
were divided into five groups by 5~7 residues, respectively. The 
binding affinity of a single mutant D98(VH)W (KD 0.11 nM) was 
increased by 3-fold compared to the parent antibody hu4D5, but 
the anti-cancer activity of the variant was not reported. They also 
suggested that further improvement in binding affinity might be 
found using alternative methods of binding selection or targeting 
more plastic or variable positions (Gerstner et al., 2002). However, 
there were no reports of success in screening variants superior to 
D98(VH)W in binding affinity and functional activity such as anti-
cancer activity until now. 
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The aim of this study was to investigate whether further 
modifications of the antibody that has been already affinity-
maturated could improve its binding affinity and subsequent 
efficacy and to establish of antibody optimization technology for 
antibody improvement strategy, using hu4D5 as a model system. 
 
Therefore, firstly, the CDR regions of Herceptin that already has 
high binding affinity to specific antigen HER2 were first changed 
by random mutagenesis, and the following screen was planned to 
select the variants with improved anti-cancer activity and binding 
affinity. In addition, since there was a possibility to increase those 
activities by mutating the framework part (or region) instead CDR 
regions (Ding et al., 2010; Kobayashi et al., 2010), it was planned to 
select new improved HER2-targeting therapeutic antibodies 
through error-prone random mutagenesis of the entire variable 
region from the selected variants and the well-established phage 
display technology.  
 
Secondly, in vitro functional anti-tumor activity, binding affinity, 
target cross-reactivity (specificity), mechanism of signaling 
inhibition and in vivo anti-tumor activity of variants were evaluated, 
and, it was also speculated how to attribute the modification of 
hu4D5 to improvement in binding affinity using molecular 






Fig. 3-1. Variable sequence of hu4D5 (Herceptin). 
 
* Key residues: VH R50, VH W95, VH Y100a, VL H91 (Kelley et al., 1993; Gerstner et al., 2002) 
CDR, complementarity-determining region; FR, framework 
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3.2 Materials and methods    
 
3.2.1 Construction of scFv libraries  
 
Phage-displayed scFv (a single chain variable fragment) libraries 
were constructed using a phagemid vector pCMTG (Oh et al., 2007) 
encoding the scFv-pIII fusion protein. The structure of the vector is 
schematically shown in Fig. 3-2A. The scFv comprising a light 
variable chain, a linker and a heavy variable chain in order was 
placed under the control of the lac promoter inducible by IPTG. 
The linker sequence is GGGGSGGGSGGSS.  
A “stop template” version of the scFv display vector which was 
generated using stop codon TGA by overlapping PCR and was 
confirmed by sequencing was used as a PCR template to generate 
libraries to inhibit re-emerging and enrichment during screening 
process.  
 
Libraries LN01 and LN02 randomized at four positions of the 
CDR-H3 (# 96, 97, 98 and 100) and at six positions of the CDR-H3 
(# 98, 100, 100b, 100c, 101 and 102), respectively, were generated by 
degenerate PCR. The Phage-displayed LN01 and LN02 libraries 
were mixed and panning procedure was carried out. To generate 
library LN03 randomized at seven positions of CDR-L3, two 
sublibraries randomizing four positions on each (#89, 90, 92, 93 and 
#93, 95, 96, 97) were generated using degenerate PCR and 
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combined, and then panning procedure was carried out. 
 
After sequence identification of isolated scFv through the panning 
process, heavy chain and light chain were constructed using dual 
vector system (pOptiVEC & pcDNA3.3, Invitrogen, USA) and 
transiently expressed in CHO-S cells as a full IgG1. After 
purification, functional anti-tumor activity of the antibody variants 
was evaluated in breast cancer cells, SK-BR-3 to select optimal 
heavy chains and light chains. The heavy chain variant selected 
from the LN01 or LN02 and light chain variant selected from the 
LN03 were cloned in dual expression vector system and transiently 
expressed in CHO-S cells as a full IgG1, resulting in “Combination 
Series C01” and “Combination Series C02”, respectively. The 
purified combinatorial antibodies were evaluated based on anti-
proliferative activities against SK-BR-3 cells.   
 
The library LN04 was randomized at six position of the CDR-L2 
(#50, 51, 52, 54, 55, 56) using the selected variants from 
“Combination Series” C01 and C02 as a template and were 
screened as described above. The LN05 library was constructed by 
error-prone PCR method for random mutagenesis of entire variable 
regions.  
 
Degenerate PCR was performed using a Bio-Rad C1000 thermal 
cycler according to manufacturer’s instructions (Ex Taq, Takara, 
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Japan). PCR condition was as follows: denaturation, 95°C for 20 sec; 
annealing, 57°C for 30 sec; extension, 72°C for 45 sec; 27 cycles. 
Error-prone PCR was conducted using 100 ng of template DNA 
with GeneMorpII Random mutagenesis kit (Stratagene, USA) 
under the 32-cycle condition of denaturing for 20 sec at 95°C, 
annealing for 30 sec at 57°C, and extension for 45 sec at 72°C. PCR 
scheme and primer sets used in this study are shown in Fig. 3-2 and 
Table 3-1, respectively. 
 
Each PCR product was retrieved using Gel and PCR Clean-up 
system (Promega, USA), and then cleaved with a restriction 
endonuclease. Similarly, the pCMTG vector was also cleaved with 
the same restriction endonuclease and treated with shrimp alkaline 
phosphatase (USB, 70092Z). Then, the fragments were ligated 
overnight at 16°C using DNA ligation system (Promega, M8225). 
 
The phagemid DNA libraries were introduced into E. coli XL1-
blue-MRF’ (Stratagene, USA) by electroporation (Sidhu et al., 2000), 
and the transformants were infected with 20 MOI (multiplicity of 
infection) and cultured overnight under the presence of Ex12 helper 
phages (Back et al., 2002) to encapsulate phagemid DNA, thereby 
generating phage particles displaying scFv fragments on its surface.  
 
In summary, constructed libraries and candidate screening 


















Fig. 3-2. Library construction map. 
(A) Overall phagemid vector pCMTG (B) LN01 




Table 3-1. PCR primer sequences used for the library construction. 
 




















Fig. 3-3. Candidate screening flow scheme. 
ELISA units and anti-proliferative activity against tumor cells were 
considered in selecting variants. The variants whose SE and RE values 
were 5 fold higher than those of negative blank were selected. And then 
further selection was preceded based on RA as indicated. SE, Screening 
ELISA unit of OD450; RE, Relative ELISA unit of OD450; RA (Relative 
activity), a ratio of IC50 of parent hu4D5 to the variant in anti-proliferative 
activity against breast tumor SK-BR-3 or gastric tumor NCI-N87 cells. 
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3.2.2 Selection of HER2-specific variants from scFv libraries 
 
To screen out HER2-specific antibody from the libraries, Maxi-
Sorp immunotubes (Nunc, 444202) were coated with human HER2-
ECD (extracellular domain of erb B2 or p185HER2 fused with Fc, 
R&D systems, USA). After that, the libraries infected with Ex12 
helper phage (IG therapy, Korea) were used at panning procedure 
as manufacturer’s instruction. Maxi-Sorp immunotubes (Nunc, 
444202) were coated overnight with 2 g/ml of human HER2-ECD 
(extracellular domain of erb B2 or p185HER2 fused with Fc, R&D 
systems, USA) at 4°C, and blocked with 2% nonfat milk in TBS-T 
for 2 hours. Phages were cultured overnight and enriched, followed 
by resuspension of the enriched phage with 2% nonfat milk in TBS-
T. The phage solutions were added to the coated immunotubes at a 
concentration of 1012 phage particles/ml, and incubated for 2 hours 
for binding with HER2-ECD.  
In particular, the stringency of panning was controlled in washing 
step. That is, the plates were washed up to 20 times with TBS-T. 
After washing, 1.0~1.5 M ammonium thiocyanate was treated for 
10 min., followed by washing with TBS-T. Then, bound phages 
were eluted with 0.1 M glycine (pH 2.2) for 10 minutes, and 
subsequently the eluted solution was neutralized with 1M Tris-HCl 
(pH 9.0). The eluent was propagated in E. coli TG1 cell (mid-log 
phase, OD600 0.5). 
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3.2.3 Screening ELISA for screening of recombinant scFv  
 
After three to five panning procedures, screening ELISA using 
soluble scFv-pIII fusion molecules prepared from E. coli clones was 
performed as described previously (Song et al., 2009). Screening 
ELISA was performed to isolate HER2-specific antibody variants. 
Individual clones were grown in a 96-well format in 200 l of 2YT 
broth supplemented with 1 mM IPTG, and the culture supernatants 
were used in ELISA to detect phage-displayed scFv that bound to 
antigen-coated plates but not to IgG-coated plates.  
To select HER2-specific antibody variants, ELISA was performed 
with human HER2-ECD or human IgG (Sigma) as coating antigens 
and anti-pⅢ antibody (MoBiTec, PSKAN3) as a detecting antibody. 
Consequently, clones expressing phage-displayed scFv that bound 
to antigen-coated plates but not to IgG-coated plates were selected. 
Maxi-Sorp 96-well microtiter plates were coated with 50 ng/50 
l/ml of recombinant HER2-ECD fused with Fc or human IgG. 
After overnight incubation at 4°C, the plates were washed three 
times with TBS-0.05% Tween 20 (TBS-T), and then blocked with 2% 
nonfat milk for 2 hours at 37˚C. The culture supernatants were 
treated for 2 hours, and then the plates were washed three times 
with TBS-T. 
After washing with 200 l of TBS-T at three times, the isolated 
antibody variants were added to Maxi-Sorp 96-well microtiter 
plates and then incubated with anti-pIII antibody (MoBiTec, 
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PSKAN3) for 1 hour, followed by incubation with the HRP-
conjugated anti-mouse Fc specific antibody (Sigma, A0168) for 45 
minutes. The plates were washed three times, TMB peroxidase 
substrate was added, and the absorbance was read at 450 nm using 
a microplate reader.  
 
 
3.2.4 Relative ELISA for measurement or screening of relative 
scFv affinity by using ammonium thiocyanate elution  
 
To assess relative binding of the soluble scFv fragment expressed 
in E. coli, ELISA was performed with thiocyanate solution 
(Johnsson et al., 1991). The procedure was similar to that described 
in Method 3.2.3., except the extra step treating the ammonium 
thiocyanate. In the next step of scFv incubation, 1 M ammonium 
thiocyanate buffer was treated for 15 min at room temperature, 
followed by washing step. The remaining steps were conducted in 
the same way as described in Method 3.2.3. 
Phagemids extracted from the selected clones were analyzed by 
DNA sequencing, and then nucleotide sequences and amino acid 
sequences of CDR were identified through NCBI IgBLAST 
(http://www.ncbi.nlm.nih.gov/igblast/).  
In summary, after antibody libraries constructed, the general 





























3.2.5 Cloning, transient expression and purification of the 
isolated variants  
 
To access antitumor activity and binding affinity of the isolated 
variants, a mammalian expression vector system pOptiVEC (for 
heavy chain expression, Invitrogen, USA) and pcDNA3.3 (for light 
chain expression, Invitrogen, USA) were used to express the full-
length IgG1 antibody. FreeStyleTM CHO-S cells (Invitrogen, USA) 
were transformed with the expression vector containing antibody 
gene according to manufacturer’s protocol. Five days after the 
transfection, the culture media were harvested and the IgG form of 
antibody variant was purified using Mabselect (GE Healthcare, 
UK). Purified IgG1 form of the antibodies were expressed 
transiently in CHO-S cells, and then purified IgGs evaluated 
functional anti-tumor activity in breast cancer cells SK-BR-3 and 
finally in gastric cancer cells NCI-N87. 
 
 
3.2.6 Anti-proliferative activity against tumor cell in vitro  
 
Effects of the isolated antibody variants on cell proliferation were 
assessed using HER2-positive breast cancer cell line SK-BR-3 (HTB-
30, ATCC ; McCoy’s 5a media, Gibco BRL) and gastric cancer cell 
line NCI-N87 (CRL-5822, ATCC ; RPMI-1640, Gibco BRL). The cells 
were seeded at a concentration of 7.5 x 103 cells/well, cultured at 
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37°C with 5% CO2 overnight, and treated with the serially diluted 
antibodies the next day. After 6 days of the treatment, viable cells 
were counted by WST-8 cell proliferation assay (Dojindo, Japan) as 
described previously (Wang et al., 2000). Twenty l of the 
reconstituted WST-8 mixture was added into each well of the plate. 
After the cells were incubated at 37°C for 2 hours, the absorbance 
was measured at 450 nm in a microplate reader.  
 
 
3.3 Results and Discussion 
 
3.3.1 Construction of variants scFv libraries  
 
Since the parent antibody hu4D5 had high affinity KD value of 0.35 
nM (Gerstner et al., 2002), it was difficult to select an antibody 
having improved affinity by general panning method. Thus, in 
order to increase the probability of the selection of high-affinity 
antibody, strategies and methods were used as follows. 
It is concerned that tight-binding "contaminant (parent or 
template antibody, hu4D5)" scFv might be dominantly selected, 
since the parent antibody hu4D5 is a highly tight-binding antibody. 
Thus, the template for each library was a modified version of 
phagemid containing a stop codon (TGA) introduced at an 
upstream or downstream position where the amino acid was to be 
mutated by overlapping PCR method. A different position 
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introducing stop codon for each library is as follows: S113 position 
of HFR4 in CDR-H3 for the libraries LN01, and LN02, C88 position 
in CDR-L3 for the library LN03 (P59 position of LFR3 in CDR-L2 
for the library LN04). 
Thereafter, a random mutagenesis procedure was carried out as 
described in the following strategy. Mutagenic oligonucleotide 
primers (Table 3-1) with degenerate NNK codons at the positions to 
be diversified were used to simultaneously introduce CDR 
diversity and remove the stop codon, whereby an open reading 
frame that encoded a scFv library member fused to a 
homodimerizing c-myc and pIII was generated. 
 
To maximize the probability of selecting variants having enhanced 
binding affinity and minimize the library size and number of 
construction, this study primarily excluded CDR-H1 and CDR-L1 
consist of 5 and 10 residues, respectively. CDR2 and CDR3 thought 
to be important to binding and specificity with antigen were 
randomized intensively. However, the strategy for site-directed 
random mutagenesis of entire CDR residues including CDR-H3 
(Kabat No. #95~102, 11 amino acid residues, W95G96G97D98 G99F100 
Y100a A100bM100cD101Y102), CDR-H2 (Kabat No. #50~65, 17 amino acid 
residues, R50I51Y52 P52aT53N54 G55Y56T57R58Y59A60D61 S62V63K64G65), 
CDR-L3 (Kabat No. #89~97, 9 amino acid residues, Q89Q90H91Y92 
T93T94 P95P96T97), and CDR-L2 (Kabat No. #50~56, 7 amino acid 
residues, S50A51S52F53 L54Y55S56) is practically impossible, since the 
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theoretical diversity of each library is 2 x 1014, 6 x 1020, 5 x 1011 and 1 
x 109 respectively, especially CDR-H2, which is too large to 
construct the libraries. 
Therefore, CDR-H2 was excluded, and in order to design the 
library with a suitable size for efficient screening, CDR-H2 R50, 
CDR-L3 H91, CDR-H3 W95, CDR-H3 Y100a positions (Gerstner et 
al., 2002) previously reported as key residues to be most critical to 
antigen binding was excluded from randomization. W95 (59% or 
82%), G99 (90% or 100%), Y100a (88% or 100%) in CDR-H3, T94 
(45%) in CDR-L3 and F53 (67%) in CDR-L2 conserved with 
frequencies more than 45% after screening from random 
mutagenesis library was also excluded from randomization. Even 
though F100 in CDR-H3 was conserved with frequency 52% 
(Gerstner et al., 2002), F100 position thought to may have a role in 
antigen-antibody interface was designated as a target site for 
randomization library construction.  
The F53 position in CDR-L2 was fixed F or W, because the 
position was conserved with F53 (67%) or W53 (55%) (Gerstner et 
al., 2002). 
Since theoretical library size of CDR-H2 composed of 14 residues 
is 1.6 x 1018, which is too large to construct the libraries, CDR-H2 
was excluded from randomization library construction, except a 
key residue, R50 and relatively invariant residues, R50 (100%), Y56 
(74%) and R58 (59%).  
 
 57 
In conclusion, total 6 residues consisting of the key residues (CDR-
L3 H91, CDR-H3 W95 and CDR-H3 Y100a) and relatively invariant 
residues (CDR-H3 G99, CDR-L2 F53, CDR3 T94) were excluded 
from randomization library construction. Libraries targeting CDR-
H3, CDR-L3 and CDR-L2 except 6 residues described above were 
constructed using NNK codon (N=A, G, T or C; K=G or T) in 
several divided subgroups. According to mutagenesis strategy in a 
stepwise fashion, LN01, LN02 and LN03 libraries targeting CDR-
H3 and CDR-L3 were constructed and actual diversity of each 
library was determined by counting the number of colonies, and 
were 9.7 x 107, 1.5 x 108 and 3.7 x 108, respectively (Table 3-2). 
 
To verify that the randomized position of each library is 
appropriately changed by PCR, DNA sequences of the scFv region 
in the recombinant phagemid from ≥ 20 clones selected after PCR, 
ligation and transformation steps, were analyzed by sequencing 
analysis. In order to prevent parental contamination of libraries, it 
was determined prior to panning whether inserted stop codon was 
present and whether the library met the following criteria: ≤ 30% 
of the frame shift frequency and ≤ 10 % of duplicated sequences. 
PCR was carried out until the library met the above requirements. 
At each step, variants selected by sequencing analysis of the 
approximately more than 100 clones obtained through panning 
were converted into the IgG format and expressed transiently in 
CHO-S cell. Finally, antitumor activity of the selected variants was 
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evaluated using cell growth inhibition assay. 
 
 








Randomized CDR positions 
CDR-H3 CDR-L3 CDR-L2 
LN01 
(degenerate) 
1.6 x 105 9.7 x 107 96, 97, 98, 100 - - 
LN02 
(degenerate) 
6.4 x 107 1.5 x 108 
98, 100, 100b,  




2 x 1.6 x 105 3.7 x 108 - 
89, 90, 92, 93 
and 




- - - 
C02 b) 
(combinatorial) 
- - - 
LN04 
(degenerate) 
2 x 6.4 x 107 1.3 x 108  
50, 51, 52, 
F53 or L53*, 
54, 55, 56 
LN05 
(error-prone) 
- 2.4 x 108 FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 
a) Transient expression of antibodies from the combinatorial libraries 
LN01 (VH) and LN03 (VL) in CHO-S cells.  
b) Transient expression of antibodies from the combinatorial libraries 
LN02 (VH) and LN03 (VL) in CHO-S cells. 
* The original F53 (VL) position of CDR-L2 was replaced to F (same as 
the original position) or W.  
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3.3.2 Selection of HER2-specific variants from scFv libraries 
  
After making the libraries, screening process was performed using 
a series of panning with a HER2-ECD-Fc as an antigen to select 
variants with enhanced anticancer activity than hu4D5 in HER2-
positive cancer cells (Fig. 3-3). 
Therefore, high-stringency screening to select an antibody having 
higher affinity than the parent antibody hu4D5 was performed as 
follows. First, washing was carried out for up to 44 hours to select 
an antibody exhibiting enhanced off-rate (Chen et al., 1999). Second, 
pre-elution was performed with 0.1 M glycine (pH 2.2) before the 
final elution (Chen et al., 1999). Third, weakly bound antibodies 
were removed by treating ammonium thiocyanate before elution 
(Macdonald et al., 1988; Wang et al., 2000). The washing step was 
performed with 0.1 M glycine (pH2.2) and 1 M ammonium 
thiocyanate sequentially or in a different order during three to five 
rounds of panning. Fourth, the antibodies with high affinity were 
enriched during successive rounds of panning by decreasing the 
concentration of HER2 ECD-Fc, from 2.0 to 0.1 g/ml.  
 
In summary, it seemed that “tight binding variant antibodies” 
with high affinity were enriched by 4 methods during successive 
rounds of panning.  
Since HER2 ECD-Fc was used as an antigen, non-specific antibody 
that binds to the Fc protein should be considered. Therefore, ratio 
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of the number of colonies from a negative antigen (human IgG or 
BSA) to that from HER2 ECD-Fc was determined, and if ratio of the 
number of colonies from a negative antigen (human IgG or BSA) 
was less than 1%, this study further proceeded with the screening. 
The enrichment factor is calculated from the input and output 
ratios. Enrichment factor is defined as: [output/input ratio of 
selection round N]/[output/input ratio of the first selection round].  
Five, eighteen and ten kinds of antibody sequences were isolated 
in accordance with panning stringency from library LN01, LN02 
and LN03 randomized at 4 residues and 6 residues of CDR-H3 and 
7 residues of CDR-L3, respectively.  
 
Because four variants from LN02 and one variant from LN03 were 
transiently expressed at extremely low levels in CHO-S cell, these 
four clones were not counted. The number of selected variants from 
CDR-H3 and CDR-L3 randomizing libraries was 5, 15 and 9, 
respectively (Table 3-3). These variants were expressed in CHO-S 
cells as an IgG format, and their proliferation inhibitory activity 
was assessed in SK-BR-3 cells. 
Since the primary purpose of this study was to improve the 
biological activity of the antibody, the anti-proliferative activity 
ratio or folds of variants was calculated as IC50 of hu4D5 / IC50 of 
variant. IC50 of variants for anti-proliferative efficacy in SK-BR-3 
cells was determined and compared with that of the parent hu4D5. 
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It was planned to select the variants as a candidate of biobetter 
antibody selected based on the anti-proliferative activity ratio in the 
SK-BR-3 cells (IC50 of hu4D5 / IC50 of the variant) of 1 or more (Fig. 
3-3).  
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All 5, 9 and 13 variants isolated from each LN01, NL02 and NL03 
did not meet the criteria, respectively, but only one AH06 isolated 
from the LN02 was the best, and the ratio of anti-proliferative 
activity was about 1.3 for SK-BR-3 cells (Table 3-3, Fig. 3-5). 
Since the variants isolated from LN01 or LN02, and LN03 have 
changed only in each CDR-H3 or L3, a new and additional 
“combinatorial variants” can be made from shuffling of the 
variants changed VL from LN03 and the variants changed VH from 
LN01 or LN02.  
Therefore, in order to confirm the possibility of the anti-cancer 
effect of the “combinatorial variants” is increased, this study 
selected 3, 8, and 8 variants met the criteria of activity ratio were 
more than 0.7, 0.8 and 0.7 from LN01, LN02, and LN03, respectively.  
And two series of the “combinatorial expressions of heavy and 
light chain variants”, C01 (CDR-H3 variants from LN01 and CDR-
L3 variants from LN03) and C02 (CDR-H3 variants from LN02 and 
CDR-L3 variants from LN03) were generated by transient 
expression in CHO-S cells.  
In case of LN02 randomized at six positions (98, 100, 100b, 100c, 
101, 102) in CDR-H3, three variants meeting the criteria, anti-
proliferative activity ratio 1.0 or more, including AH06, were 
selected. For the heavy chain and light chain shuffling or 
combination, “Combinatorial Expression Series” C02 step was 
implemented in combination with the selected variants from CDR-
L3 randomizing library, in a similar manner. 
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All variants selected from LN03 targeting seven positions (89, 90, 
92, 93, 95, 96, 97), dividing into two sublibraries, four residues on 
each (89, 90, 92, 93 and 93, 95, 96, 97) in CDR-L3 did not meet the 
criteria, but “Combinatorial Expression Series” C01 and C02 step 
was implemented using eight variants whose anti-proliferative 
activity ratio was more than 0.7 in combination with the selected 
variants from CDR-H3 randomizing library. 
In order to check the possibility of the anti-cancer effect is 
improved through combination between the selected variants from 
CDR-H3 and CDR-L3 randomizing libraries, pOptiVEC (for heavy 
chain expression) and pcDNA3.3 (for light chain expression) 
vectors were constructed and expressed in CHO-S cell in 
combination to produce as IgG1 format combined with heavy and 
light chains. 
In the Series C01, total 24 variants by the combination of three 
CDR-H3 variants from LN01 and 8 CDR-L3 variants from LN03 
were expressed transiently in CHO-S cells. Twenty three variants 
were purified and their anti-proliferative activity against SK-BR-3 
cells was assessed. However, there was no variants having the 















Fig. 3-5. Results of antibody libraries screening. Ratio of IC50 for in vitro anti-tumor efficacy in SK-BR-3 
breast cancer cells (variant/hu4D5). The modified variant, AH06D, with substitution at D98 was artificially 
derived from the parental variant AH06 to evaluate the effect of position 98 in CDR-H3.  
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In C02, total 64 variants by the combination of eight CDR-H3 
variants from LN02 and eight CDR-L3 variants from LN03 were 
expressed transiently in CHO-S cell. As a result of measuring the 
anti-proliferative activity of 58 kinds of IgG selected from C02 
against SK-BR-3 cells, there were 15 variants having the activity 
ratio of 1.0 or more. Unfortunately, there was no variants having 
significantly enhanced anti-cancer activity than AH06 derived from 
LN02 (Fig. 3-5).  
To examine the effect of randomization of CDR-L2, LN04 
randomized at 6 positions (#50, 51, 52, F53 or L53, 54, 55, 56) of 
CDR-L2 was constructed using 15 variants selected from C02 as 
PCR templates. Two variants with the anti-proliferative activity 
ratio of 1.0 or more were obtained, but there was no variants 
having significantly enhanced anti-cancer activity than AH06 (Fig. 
3-5). 
Unlike LN01~LN04 series randomizing CDR-H3, L3 and L2 and 
screened for anticancer activity, LN05 targeting entire variable 
regions was constructed by error-prone PCR method using two 
variants (such as A083 and A085) selected from LN04, as PCR 
templates. As a result of cell proliferation inhibition assay in SK-
BR-3 cells, there were 7 variants having activity ratio of 1.0 or more. 





In summary, 153 variants were obtained by the stringent panning 
procedure from the randomized libraries. After conversion into 
IgG1 format, the selected variants were expressed transiently in 
CHO-S cell and purified by Protein A affinity chromatograpy to 
produce antibody variants. The total 139 variants were well 
expressed as IgG form with structural stability, variants were 
selected based on the anti-proliferative activity ratio in the SK-BR-3 
cells (IC50 of hu4D5 / IC50 of variant). Biological activity of the 
selected variants was preferentially measured in well-known breast 
cancer cell line SK-BR-3 since the final goal was to obtain improved 
antibodies in not only binding affinity but also biological activity 
(Table 3-3, Fig. 3-5).   
 
And several variants such as AH06 selected in the screening 
variants whose ratio were more than 1.1 were further tested for 
anti-cancer activity against HER2-positive gastric cancer cell NCI-
N87 and binding affinity using BIAcoreTM. Anticancer activity of 
the selected variants including AH06, AH16 and A091 were 
measured in another important HER2-positive gastric cancer cells, 
NCI-N87. Besides, binding affinity for HER2-ECD was precisely 
measured using BIAcoreTM to see whether the binding was 





3.3.3 Inhibitory effects of the variants on cell proliferation  
 
Anti-proliferative effect of antibody variants from constructed 
library was examined against breast cancer SK-BR-3 cells. Most 
effective variants including AH06, AH16, A091 were finally 
selected (Table 3-4). The anti-proliferative effect of the selected 
variants was also assessed in another HER2 over-expressed gastric 
cancer NCI-N87 cells (Fig. 3-6). The efficacy in vitro of AH16 having 
approximately 2-fold higher binding affinity compared to hu4D5, 
which is similar to D98W, was similar to that of hu4D5. Also, other 
variants, AL07, AH12 and A082 showed the anti-proliferative 
activity similar to hu4D5 (data not shown). 
The cell growth inhibitory activity against NCI-N87 of AH06 (IC50 
0.12 g/ml = 0.81 nM) was increased 7.22 times compared to the 
parental antibody hu4D5 (IC50 0.88 g/ml = 5.88 nM) (Fig. 3-6). On 
the other hand, hu4D5 D98W was increased 4.3-fold in the KD value 
against HER2, but anti-proliferative effect against SK-BR-3 and 
NCI-N87 was low compared to the parental hu4D5 (Table 3-4 and 
Fig. 3-6). Interestingly, although binding affinity of A091 was 
decreased 2-fold, anti-proliferative effect against NCI-N87 was 
improved 2.95-fold (IC50 0.33 g/ml = 1.99nM). These results show 
the functional biological activity of the antibody is not necessarily 
proportional to antigen-binding affinity.  
Therefore, additional biological activity (or efficacy), such as 
binding affinity, cross-reactivity, specificity, signaling inhibitory 
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Table 3-4. Deduced sequences, anti-cancer activity and binding kinetics of representative variants (as 












* To evaluate effect of position 98 in CDR-H3, W98 in CDR-H3 of AH06 was substituted with D98. ** Direct engraftment of changed 
residues of CDR-H3 from the Libraries, LN01 and LN02. CDR, complementarity-determining region; FR, framework; dashes indicate 
sequence identical to that of hu4D5. Values for kon and koff are measured at 25°C by SPR on BIAcore. The relative affinity, reported as 
KD (parent)/KD (variant) indicates the fold increase in binding affinity versus the parental antibody hu4D5. ND : not-determined. 
Breast cancer cells (variant/hu4D5). The modified variant, AH06D, with substitution at D98 was artificially derived from the parental 
variant AH06 to evaluate the effect of position 98 in CDR-H3.  
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activity of AH06 showing increased anti-proliferative activity were 
investigated further. And also, the in vivo xenograft anti-cancer 
activity of AH16 and A091 which isolated earlier than AH06 was 















Fig. 3-6. Inhibitory effects of hu4D5 variants on NCI-N87 cell 
proliferation. The cells were treated with the indicated concentrations of 
variants for 6 days. Cell viability is expressed as a percentage relative to 
untreated control. Data represents the average SD of triplicate 
determinations. The cell growth inhibitory activity against NCI-N87 of 
AH06 (IC50 0.12 g/ml = 0.81 nM) was increased 7.22 times compared to 
the parental antibody hu4D5. 
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3.3.4 Influence of substituted residues on biological activity 
 
The variant AH06 was derived from the library LN02, and has an 
unchanged light chain and a substituted heavy chain with the 
changes in D98W, M100cF, D101A, Y102L of CDR-H3 (Table 3-4). 
AH06 also showed substantially enhanced binding affinity. KD 
value of AH06 was about 7.4-fold and 2.4-fold higher compared to 
those of the parent hu4D5 and D98W, the previously reported 
variant, respectively (Gerstner et al., 2002) And the variant AH06 
had 7.2–fold enhanced anti-proliferative activity in comparison to 
hu4D5 (Table 3-4, Fig. 3-6). Even though A091 showed a strong 
growth inhibitory activity of about 3 times higher than hu4D5 in 
gastric cancer cell NCI-N87, binding affinity for HER2 was found 
rather decreased (Table 3-4). Thus, there was no direct correlation 
between the binding affinity and its biological activity in A091 
variant. 
The variant AH06 derived from the library LN02 has an 
unchanged light chain and a mutated heavy chain with the changes 
in D98W, M100cF, D101A, and Y102L of CDR-H3. The anti-
proliferative activity ratio of C02, a combination of one heavy chain 
variant AH06 and eight light chain variants derived from the 
library LN03 randomizing CDR-L3 was all 1.0 or less , except for 
A058 (Table 3-3, Fig. 3-5). Therefore, a conclusion that the heavy 
chain with the changes in D98W, M100cF, D101A, and Y102L of 
CDR-H3 can form the optimal combination with the unmodified 
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light chain of hu4D5 was reached. 
Since it was reported that D98W containing the substitution of Glu 
with Trp at position 98 in CDR-H3 has increased binding affinity 
constant (KD) of about 3 times higher than hu4D5 (Gerstner et al., 
2002), a modified version of AH06 (AH06 W98D), in which Trp was 
substituted with Glu at position 98, was constructed to evaluate 
whether the mutation has any impact.  
 
The binding affinity of AH06 W98D was also 3.1 times higher 
compared to hu4D5 (Table 3-4), suggesting that the changed 
sequence of "F100c A101 L102" contributes to the improvement on 
its binding affinity of 3.1-fold for HER2-ECD molecule. The binding 
affinity of D98W was improved about 4.3-fold whereas AH06 
showed a 7.4-fold higher binding affinity than hu4D5, which 
suggests W98 and the F100c A101 L102 sequence synergistically 
improve the binding affinity. (Refer to Molecular modeling analysis 
part of Chapter 4.) 
 
 
3.3.5 Construction of variants scFv libraries  
 
3.3.5.1 Strategic aspect  
 
In order to increase the chance to find the variants having 
enhanced affinity than hu4D5, the differentiated strategy used for 
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library construction was randomization of M100c, D101 and Y102 
positions considered as conserved in CDR-H3 rather than fixing. 
Resi B. Gerstner et al. (Gerstner et al., 2002) did not carry out the 
mutagenesis study out on this on all these positions, M100c, D101 
and Y102. Besides, it was not reported whether the binding affinity 
is increased, decreased or unchanged by substitutions of several 
residues including these positions of hu4D5. Thus, these three 
positions were included in the random library construction. 
Therefore, the libraries, LN01 and LN02 were constructed by 
randomizing eight positions of CDR-H3 such as G96, G97, D98, 
F100 and A100b. M100c, D101 and Y102 positions not attempted in 
the previous mutagenesis study were also included. The targeted 
positions were divided into LN01 and LN02 libraries with no more 
than six residues targeted in each. For CDR-L3, library LN03 was 
constructed by randomizing seven positions, except for a key 
residue, H91 and an invariant residue conserved with frequency 
52%, T94 (Gerstner et al., 2002). In case of CDR-L2, library LN04 
was constructed by randomizing six positions, except for F53 
position. F53 or W53 was used at the 53 position. The screening 
process of each library was carried to the step-by-step (Fig. 3-3).  
 
In summary, a series of processes for screening tighter binding 
variants having improved binding affinity compared to hu4D5 was 
performed as follows. Several libraries randomizing CDR-H3, 
CDR-L3 and CDR-L2 were constructed one by one. Among variants 
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obtained from each library by panning with HER2-ECD-Fc, some 
variants were selected using cell growth inhibition assay. Selected 
variant was used as a template required for library construction for 
the next step. By doing this, this study tried to Fig. out whether 
antitumor activity of the variants can be improved synergistically 
by combined changes in the two or more regions, not limited to any 
effect by that in the a certain region among CDR-H3, L3 and L2.  
 
 
3.3.5.2 Analysis for appearance frequency of CDR residues  
 
The variants selected by stringent panning with high selection 
pressure were analyzed to determine which residues were selected 
at randomized positions (Fig. 3-7). 
 
 
3.3.5.2.1 Library LN01   
 
Sequence pattern of five variants derived from LN01 randomized 
at four positions (#96, 97, 98 and 100), except for seven positions 
(#95, 99, 100a, 100b, 100c, 101, 102), corresponding to the first half 
of the CDR-H3 among 11 residues of CDR-H3 was analysed (Fig. 3-
7 A). In consequence, parent-typeresidue was conserved with 60% 
frequency at both  positions 97 and 100, whereas relatively diverse 
residues, different from the original residue were shown at 
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positions 96 and 98. Their anti-proliferative activity of 5 variants 
derived from LN01 was lower than parent hu4D5, indicating that 
randomization of four positions (#96, 97, 98 and 100) out of 11 

















               C                           D     
 Fig. 3-7. Distribution of appeared amino acids at randomized 
positions of CDR.  A. Library LN01 : 4 positions of CDR-H3,   
B. Library LN02 : 6 positions of CDR-H3, C. Library LN03 : 7 (4 and 4) 
positions of CDR-L3,  D. Library LN04 : 6 positions of CDR-L2  
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3.3.5.2.2 Library LN02   
 
Sequence pattern of five variants derived from LN02 randomized 
at seven positions (#95, 99, 100a, 100b, 100c, 101, 102), except for 
four positions (#96, 97, 98 and 100), corresponding to the second 
half of the CDR-H3 among 11 residues of CDR-H3 was analysed 
(Fig. 3-7 B). In consequence, parent-typeresidue were conserved 
with ≥ 40% frequency at #98, 100 and 100b position. At 98 position, 
the parent-type D occured in 50% of the selected clones and was 
replaced with W in 35.7% of selected clones. 
Interestingly, at the neighboring #100c, 101 and 102 position, F, A 
and L occurred dominantly in selected clones. To conclude, the 
strategy for LN02 randomized at six residues was thought to be 
more successful than the strategy for LN01 randomized at four 
residues of 11 residues in CDR-H3 region since AH06 was derived 
from LN02.  
The #98 and 100 positions were designated as random positions in 
both LN01 and LN02. Both libraries showed a similar amino acid 
residue and frequency at the #100 position, but not at the #98 
position (Fig. 3-7 B). At the #98 position of LN01, variants were not 
survived under stringent panning procedure by the strategy to 
exclude four positions (#96, 97, 98 and 100) from randomization, 
corresponding to the second half of CDR-H3. At the #98 position of 
LN02, variants were not survived under stringent panning 
procedure by the strategy to exclude two positions (#96 and 97 
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position) from randomization, corresponding to the first half of 
CDR-H3.  
It is difficult to explain the reside frequency observed at position 
98 in LN01 and LN02. However, the interaction between fixed 
residues in the first half and the second half of CDR-H3 and the 
residue at position 98 could affect overall binding affinity, 
interaction between VL and VH, and stability of isolated variants. 
Therefore, it might be interpreted as the consequence by selection 
of variants survived under the stringent panning pressure.  
In this study, the thermodynamic analysis of residue-residue 
interaction was attempted. Since it was practically impossible to 
analyze all of the isolated variants using computer modeling, AH06 
having the best efficacy and its related variants were analyzed as a 
representative example. (Refer to Modeling part of Chapter 4.) 
 
 
3.3.5.2.3 Library LN03    
 
The sequence pattern of nine variants derived from LN03-1 and 
LN03-2 were analyzed (Fig. 3-7 C). The sub-library LN03-1 was 
randomized at four positions, #89, 90, 92 and 93, corresponding to 
the first half of the CDR-L3 and fixed at the #91 position known as 
a key residue and the positions #94, 95, 96 and 97 corresponding to 
the second half of the CDR-L3. The sub-library LN03-2 was 
randomized at four positions, #93, 95, 96 and 97, corresponding to 
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the second half of the CDR-L3 and fixed at the #91 position known 
as a key residue and the positions #89, 90, 92 and corresponding to 
the first half of the CDR-L3. All resulting residues at the #89, 90 and 
92 positions in LN03-1 after randomization were identical to 
parental ones. How to explain the results? 
It could be speculated that variants from the library LN03-1 
randomized at the #89, 90, 92 and 93 positions, might not be 
survived under stringent panning procedure or/and under the 
strategy to fix four positions (#94, 95, 96 and 97 positions), 
corresponding to the second half of CDR-L3. 
 
Sequencing analysis after library construction confirmed that the 
LN03-1 was practically randomized at the #89, 90, 92 and 93 
position of CDR-L3 using degenerate PCR (data not shown). 
Therefore, it can be speculated that LN03-1 derived variants may be 
unable to be selected by high stringent panning, because the variant 
may have low binding affinity or strength not enough to tolerate 
the selection pressure without randomization in second half of the 
CDR-L3 (#94, 95, 96 and 97) although the first half of the CDR-L3 
(#89, 90, 92 and 93) is changed.  
Actually, AL04 was the sole variant thought to be derived from 
LN-03-1, which may be explained by that CDR-L3 sequence of 
AL04, “Q89Q90H91Y92L93T94P95P96T97” results from the substitution 
only at the #93 position among randomized at four positions of 
LN03-1, T94, P95, P96 and T97. 
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Alternatively, AL04 could be interpreted as a variant derived from 
LN03-2 randomized at four positions, #93, 95, 96 and 97, 
corresponding to the second half of the CDR-L3 and fixed at four 
positions, #89, 90 and 92 corresponding to the first half of the CDR-
L3. That is to say, AL04 substituted at the #93 position, but not at 
the #95, 96 and 97 positions was the only survivor under stringent 
panning procedure. However, it could not determine which of 
these two possibilities would be appropriate. 
However, it is more than true that the variants randomized at the 
#89, 90 and 92 positions did not appear as if the positions had been 
designed to be fixed rather than randomized. Therefore, this 
indicates that randomization of the first half of the CDR-L3 is 
extremely limited in case of fixing the second half of the CDR-L3.  
 
It can be speculated that the selection pattern by complicated 
interactions between the first half and second half of CDR-L3 might 
be caused by screening from the library LN03-1 fixing the 89, 90 
and 92 positions, even though it was confirmed by sequencing to be 
sufficiently randomized at the positions. However, it was unable to 
confirm whether this speculation was appropriate, since this study 
could not actually get the basic quantitative data.  
 
The screening pattern of variants unsubstituted in the 89, 90 and 
92 positions despite the design as randomizing positions, like in a 
case of LN03-1, did not appear in the LN03-2. It could be 
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speculated that the variants randomized at the #93, 95, 96 and 97 
positions are unaffected by residues at the #89, 90 and 93 positions 
and selected despite high selection pressure. Alternatively, it could 
mean that the first half “Q89Q90H91Y92” should need the second half 
“T94P95P96T97”. 
It also suggests that intact parental sequences of CDR-L3 are 
required for interactions between light and heavy chains or binding 
with antigen HER2. Alternatively, it suggests that the variants 
substituted in the second half of CDR-L3 could be selected only 
when the first half of CDR-L3 is intact.  
 
Since the parental sequences were strongly conserved not only at a 
key residue position 91 but also 89, 90 and 92 positions, not 
conserved, corresponding to the first half of CDR-L3, these three 
positions as well as position 92 are likely to have important roles 
for binding with HER2 and/or stability of the antibody variant 
itself.  
That is, it may be possible to infer that the four residues function 
as “one unit” and key residues, and have very important roles for 
binding and interaction of the antibody. If evidence supporting the 
hypothesis from quantitative analytical data and modeling analysis 
is provided, the four residues, #89, 90, 91 and 92 could be called 
“key regions”, “key domain” or “key peptides”  
 
There could be several possible interpretations about the 
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screening results with LN03, as above described. But the strategy 
randomizing the first half of CDR-L3, #89, 90, 91 and 92 positions, 
and the second half of CDR-L3, #93, 95, 96 and 97 positions was not 
efficient to original purpose for the improvement of antitumor 
activity, because the anti-proliferative activity ratio of selected 9 
variants from LN03 was under 1.0 (≤ 1.0). 
Because the isolated variants from LN03-1 appeared to unchanged 
despite randomization, it may be questionable whether there were 
problems with library construction methods, strategies and 
screening methods. As mentioned earlier, sequencing analysis for 
above 20 clones confirmed that there were no problems with library 
construction, therefore, it might be needed to double-check the 
strategies and screening methods. But, it was thought to be not a 
big problem as well, since we intended to further enhancement of 
antitumor activity and succeeded screening from LN02 library 
under stringent panning.  
 
In case of CDR-L3 consisting of nine residues, the strategy 
randomizing six residues of the first half and six residues of the 
second half may be more efficient to select improved variants than 
the strategy randomizing four residues of the first half and four 
residues of the second half, used in this study. 
 
The LN01 strategy randomizing four positions of the second half 
of the CDR-H3 consisting of 11 residues was not efficient to 
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improve antitumor activity, although the variants having diversely 
changed residues were selected from LN01. Variants showing more 
improved antitumor activity than AH06 variant derived from LN02 
randomized at six positions were not isolated from LN01.  
 
 
3.3.5.2.4 Library LN04      
 
There were total 6 variants derived from LN04 library and 
sequenced in this study. Out of 6, 3 variants were expressed in 
CHO-S cells and their anticancer efficacy was evaluated (Table 3-3, 
Fig. 3-5). The other 3 variants, AL11, AL12 and AL16 were not 
expressed in CHO-S cells and should not be listed, however, they 
were counted as isolated variants in sequence analysis. 
PCR templates of LN04 library targeting CDR-L2 were the 
variants derived from LN01, LN02, C01 and C02. The details were 
as follows: the LN01, LN02 and LN03-derived variants having not 
worse antitumor activity than hu4D5 (anti-proliferative activity 
ratio ≥ 0.7), the C01 and C02-derived variants having not worse 
antitumor activity than hu4D5 (anti-proliferative activity ratio ≥ 
1.0). This was a major difference from the library LN01, LN02 and 
LN03 using parent antibody hu4D5 as a template.  
 
Except for PCR template, library construction and panning 
strategy were carried out by same way. Six positions among seven 
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residues of CDR-L2 were randomized, except for fixing the #53 
position with F53 or W53. As a result of screening, six variants were 
selected from LN04 library targeting CDR-L2. And the variants had 
F53 and W53 with 50% identical frequency, as designed, diverse 
residues appeared in the other randomized positions of LN04-
derived variants (Fig. 3-7 D).  
 
Judged from anti-proliferative activity ratio of LN04-derived 
variant (Fig. 3-5), the combining strategy CDR-H3 variants with 
CDR-L3 variants was not efficient to improve antitumor activity, 




3.3.5.2.5 Library LN05 (by error-prone PCR)  
 
In order to increase the possibility of the anti-cancer effect, this 
study tried to randomize entire variable region including FR region, 
unlike a screening CDR randomization by degenerate PCR for 
some position in the construction library LN01, LN02, LN03 and 
LN04. So, the library LN05 was constructed using error-prone PCR 
method at low range of mutation frequency (4.5 mutations/kb). 
Performing 30 cycles of PCR using 500 ng of template DNA, it was 
confirmed the mutation frequency of 4~8 mutations/kb by 
sequencing analysis. 
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And the library LN05 had 2~7 substituted amino acids per scFv 
molecule, it generally corresponds to the mutation frequency of 4~8 
mutations/kb since the size of VL or VH are approximately 330 bp 
and thus it is considered that a couple of amino acids are 
substituted in each chains. Sequence analysis of 17 variants selected 
from LN05, except variant not expressed or expressed at an 
extremely low level showed that 1~4 amino acids were substituted 
(Fig. 3-8).  
 
With LN05 library screening method, A091 variant was selected 
by relative ELISA, target binding affinity and in vitro anticancer 
activity (Table 3-3, 3-4). AH06 derived from early library LN03 and 
its binding affinity was improved 10 times more than that of 
Hu4D5. Although random library was constantly constructed and 
kept performing screening processes to select the variants superior 
to AH06 from several series of library, the superior one to AH06 
could not be obtained on the basis of anticancer activity and 


























Fig. 3-8. Substituted positions in VL-VH region of the variants 
isolated from LN05. Out of total 31, 6 variants were not expressed, 3 
variants exhibited low efficacy and 5 variants were not substituted, 






3.3.6 Selection of HER2-specific variants: summary  
 
After panning with 3~5 cycles with HER2 ECD-Fc as an antigen, 
from randomized scFv phage libraries LN01, LN02 and LN03, 
phage ELISA was performed to positive clones with more than 5-
fold ELISA value (OD450 ≥ 0.5) relative to negative blank. Also, 
relative phage ELISA using 1M ammonium thiocyanate 
(Macdonald et al., 1998; Wang et al., 2000) selected positive clones 
(OD450 ≥ 1.0). 
A mixture of such 16 variants selected form those libraries was 
used as a template to construct CDR-L2 randomized library LN04 
as size as about 108 levels. From these libraries, variants were 
selected with the same method as libraries LN01, LN02, LN03.  
To evaluate the anti-tumor activity of isolated variants against 
tumor cells, isolated variants were converted scFv variants into an 
IgG1 format, and transiently expressed in CHO-S cells. If the 
expression level of the IgG variant was less than 10~20% of that of 
hu4D5 or there was a problem with purity, e.g., aggregation and 
inappropriate assembly of heavy and light chains, the whole 
expression experiments were repeated several times to double 
check.  
The deduced sequences analysis of representative variants, AH12, 
AH06, AL07, AH16, A058 and A091, selected from each library 
besides AH06 (Table 3-4) indicates that modification of libraries 
LN01 and LN03, except LN02, was not efficient to improve 
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biological functional activity compared to the parent hu4D5.  
 
Changes of residues to W98, F100c, A101 and L102 in CDR-H3 
region of AH06 variant played the most important role for 
improvement of the binding affinity compared to that of hu4D5. On 
the other hand, the anti-tumor activity of A058 which had the 
residues substituted with W98, F100c, A101, L102 in CDR-H3 
(identical to AH06) and 3 residues substituted with Q93, A96 and 
S97 in CDR-L3 against SK-BR-3 was similar to that of hu4D5, 
however its HER2 binding affinity KD was reduced to half that of 
hu4D5. Therefore, the data indicate that the modification of CDR-
L3 is unable to contribute to largely the improvement of HER2 
binding affinity. 
 
A091 variant had 2 point-mutated residues VL FR3 T73S, VH FR2 
P41R in extra CDR region by error-prone mutagenesis in addition 
to 4 substituted positions of CDR-H3 (as like AH06), 3 substituted 
positions of CDR-L3, and 5 substituted positions of CDR-L2. Anti-
cancer activities of A091 was similar and increased to about 3 fold 
to that of hu4D4 against SK-BR-3 and NCI-N87, respectively, but, 
its HER2 binding affinity KD was reduce to half  that of hu4D5 
(Table 3-4).  
Taken together, substitution of other positions in CDR-L3 and 
CDR-L2 besides the positions substituted with W98, F100c, A101 
and L102 in CDR-H3 did not largely influence anti-cancer activities 
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against SK-BR-3 cells, but negatively influenced their binding 
affinities.  
 
However, only based on binding affinities of AH06, A091, A058, 
and others, it seems that it is unable to conclude that CDR-H3 is the 
only important determining region for improvement of antigen 
HER2 binding. Instead, judging from results of library construction 
and stringent panning, it is thought to may be more proper 
conclusions that possibilities for improvement of binding affinity 
potentially exist in CDR-H3 region of hu4D5, and this study just 






It was generated the variant AH06 whose binding affinity was 
enormously increased to 7.4-folds and also its anti-cancer activity 
against NCI-N87 cell was improved to about 7-folds compared to 
those of parent antibody hu4D5.   
Namely, 139 variants were isolated from panning and screening 
procedures, and they were produced by transient expression in 
CHO-S cell, and purified as IgG solution whose purity and 
quantity were sufficient to screen and perform various evaluation. 
And the isolated variants were evaluated by anti-tumor activities 
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against breast cancer cell SK-BR-3 and gastric tumor cell NCI-N87 
cell in vitro.  
 
In summary, a series of antibody discovery steps were performed 
to screen the variants with improved biological activities by using 
antibody CDR mutagenesis and phage display technologies. 
Through this process, the upstream antibody engineering 
technology, such as antibody optimization, required to discover 
and improve biological efficacy of various therapeutic lead 




























Evaluations and Characterizations of  




To be developed as a novel antibody drug having the clinical 
usefulness, the antibody should meet the standards or criteria as a 
novel drug, such as proper biological activity (efficacy) and 
reduced side effects. In addition, the convenience of drug 
administration for patient is also important, therefore, the 
pharmacokinetic properties of drug must be evaluated to choose 
the route of administration. These biological characteristics should 
be eventually tested and evaluated through the clinical trials 
process. 
 
However, prior to clinical trials for the practical and actual 
evaluation, the values and feasibility as a clinically useful drug 
should be evaluated in terms of efficacy, safety and stability in 
animal model (Xu et al., 2015; Knezevic et al., 2015) through 
preclinical studies.  
And also, before proceed to the preclinical test trials requiring 
huge costs for acquiring the data or information about efficacy, 
safety, stability and pharmacokinetics data of the drug, interim or 
discovery evaluation process is also necessary assess fundamental 
values as a novel drug whether it possesses effective biological 
activity and safety or not.  
 
For example, in vitro activity and in vivo efficacy is necessary, and 
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thus, the evaluation of anti-proliferative activity against tumor cells 
harboring its specific antigen on the cell surface should be needed 
in case of anti-cancer antibodies. In addition, the physico-chemical 
binding affinity should be tested in order to interpret in vitro anti-
proliferative activity. It is desirable to evaluate anti-cancer efficacy 
in animal models by reference to in vitro activity. Therefore, in vivo 
tumor xenograft model is widely used for efficacy assessment of 
anti-cancer antibody. 
 
In addition, the action mechanism of anti-cancer antibody is well-
known: the anti-cancer activities are exerted by not only inhibition 
of signaling mediated by the target antigen, but also effector 
functions such as ADCC (antibody-dependent cell cytotoxicity) 
(Baselga et al., 2001) and CDC (complement dependent 
cytotoxicity) (Kubota et al., 2009) through the IgG1 Fc region 
recognized by effector cells such as macrophages and natural killer 
cells. Therefore, it is recommended to perform the ADCC and/or 
CDC activity test. Herceptin is also known to induce ADCC to 
some extent (Barok et al., 2007).  
 
In vitro specificity (cross-reactivity) test is needed to evaluate the 
safety of antibody. The antigenic specificity of antibody can be 




When therapeutic protein such as antibody is administered into 
human body it might be able to act as a new foreign antigen itself 
and induce formation of anti-therapeutic protein antibody 
immunogenicity of therapeutic protein should be evaluated (Xu et 
al., 2015; Knezevic et al., 2015). The test for immunogenicity 
induction can be carried out in silico (Bryson et al., 2010). However, 
since the immunogenicity test in a big animal, monkey provides 
more reliable and predictable information, the result of in silico 
immunogenicity test prior to preclinical phase has a meaning only 
as a reference. 
 
In this study, feasible items were evaluated among in vitro and in 
vivo activity and safety tests. Therefore, in vitro functional anti-
tumor activity, binding affinity, target cross-reactivity (specificity), 
mechanism of signaling inhibition and in vivo anti-tumor activity of 
variants such as AH06 were evaluated, and, it was also speculated 
how to attribute the modification of hu4D5 to improvement in 









4.2 Materials and Methods 
 
4.2.1 SPR assay for affinity measurement of variants  
 
The SPR (surface plasmon resonance) biosensor (BIAcore™-2000) 
was used to detect antibodies against HER2-ECD. After 
immobilization of HER2-ECD molecule onto the surface of a M5 
sensor chip (GE Healthcare, USA), antigens were immobilized on 
the surface of a M5 sensor chip using an amino coupling method as 
described previously (Johnsson et al., 1991), at a level of 
approximately 90~130 response units.  
HER2-ECD was covalently coupled by activation of the biosensor 
chip using N-ethyl-N’-(3-dimethylaminopropyl)carbodiimide and 
N-hydroxy-succinimide. HER2-ECD was diluted to approximately 
30 g/ml in 10 mM sodium-acetate, pH 4.8, and injected at 5 
l/min flow rate to achieve approximately 90~130 response units 
of coupled proteins.     
A solution of 1 M ethanolamine was injected as a blocking agent. 
For kinetic measurements, 5-fold, serially diluted antibodies were 
injected with increasing concentrations (from 0.032 nM, 0.16 nM, 
0.8 nM, 4 nM, 20 nM to 100 nM) at flow rate of 10 l /min for 5 min, 
followed by injecting a running buffer for 30 min to monitor 
dissociation. Equilibrium dissociation constants, KD values from 
surface plasmon resonance measurements were calculated as 
koff/kon. 
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4.2.2 Domain specificity analysis of variants to HER2-ECD 
antigen (indirect ELISA)  
 
To determine HER2 domain specificity of isolated variants, ELISA 
was performed with recombinant ∆HER2-ECD (HER2-ECD, which 
is a partially deleted form of domain IV consisting of 562 amino 
acids from residue 22 to residue 584 of HER2) (Genentech Patent 
US6949245, 2005) fused with Fc or HER2-ECD fused with Fc (R&D 
system, USA) as coating antigens. Maxi-Sorp 96-well microtiter 
plates (Corning, USA) were coated with 0.5 g/ml of recombinant 
∆HER2-ECD fused with Fc or HER2-ECD fused with Fc (R&D 
system, USA). 
After overnight incubation at 4°C, the plates were washed with 
TBS-T and blocked with 5% nonfat milk. After the plates were 
treated with the isolated antibody variants, and then incubated 
with HRP-conjugated anti-human kappa chain (Sigma, USA). TMB 
peroxidase substrate was added and incubated for 20 min., and the 
absorbance was read at 450 nm using a microplate reader. ELISA 
analysis was performed using methods as described previously 







4.2.3 Cross-reactivity analysis of variants to other receptor 
tyrosine kinases (indirect ELISA)  
 
To analyze cross-reactivity of the antibodies to receptor tyrosine 
kinases other than HER2, Maxi-Sorp 96-well microtiter plates were 
coated with 1 g/ml of Fc-fused ECD of PDGFRβ, VEGFR2, IGF-IR, 
FGFR3 (IIIc), EGFR, HER3 or HER4 (R&D systems, USA), or 2 
g/ml of HGFR/c-Met ECD-Fc (R&D systems, USA). After 
overnight incubation at 4°C, the plates were incubated with 30 nM 
of the isolated antibody variants at 37°C for 2 hours.  
After washing with TBS-T, the plates were treated with anti-goat 
IgG-peroxidase antibody (Sigma, A5420) or anti-mouse IgG-
peroxidase antibody (Sigma, A9044) at 37°C for 1 hour. TMB 
substrate solution was added and incubated for 20 minutes, and the 
absorbance was read at 450 nm using a microplate reader. ELISA 
analysis was performed using methods as described previously 
(Yoon et al., 2006).  
 
 
4.2.4 Inhibitory effect of variants to HER2 signaling 
(immunoblot) 
 
The ability of isolated antibody variants to inhibit signaling 
activation was assessed in HER2 positive gastric cancer cells, NCI-
N87 (CRL-5822, ATCC). The cells were seed at a concentration of 2 
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x 105 cells/ml into a 100-mm cell culture dish and treated with 10 
g/ml of antibodies for 16 hours to analyze pAkt and 72 hours to 
analysis p27, and lysed by adding RIPA buffer (1.0% NP-40, 0.5% 
deoxycholic acid, 0.1% SDS, 50 mM Tris-HCl, pH8.0) with 1 mM 
EDTA, 1mM PMSF, protease inhibitor cocktail (Thermo, USA) and 
phosphatase inhibitor cocktail (Thermo, USA). Western blot 
analysis was performed using methods as described previously 
(O'Brien et al., 2010). 
 
Harvested cells were centrifuged at 15,000 rpm for 30 minutes at 
4°C and the supernatant was isolated. Protein concentration was 
determined using the Bradford method. 20 g of protein samples 
were separated by SDS–PAGE, and transferred onto PVDF 
membrane, and then blocked with 5% nonfat milk for 1 hour, and 
incubated overnight at 4°C with specific primary antibodies. 
Subsequently, the membrane was washed and incubated with 
HRP-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch, 
Europe). The membrane was reacted with an enhanced 
chemiluminescence kit (Amersham Biosciences, USA), and 







4.2.5 Antitumor efficacy of variants in vivo xenograft model 
 
BT-474 (HER2 positive breast cancer) cells were inoculated in the 
concentration of 5 x 107 cells/mouse (200 l) to 5-week old female 
athymic nude mouse (Balb/c), subcutaneously, after implanting 17 
-estradiol and norgestrel pellets 24 hours prior to inoculation 
(Liang et al., 2010). After reaching 80~100 mm3 in tumor size, 
antibodies were administered at the dose of 20 mg/kg for 4 weeks, 
twice a week, intraperitoneally. After completion of the test, the 
tumor tissue for all test groups were removed and measured by the 
weight and volume. 
 
Anti-cancer activity was estimated as the percentage of inhibition 
rate (IR %) of tumor volume compared the tumor volume of 
experimental group with the tumor volume of control (vehicle) 
group.  
* Tumor volume (mm3) = (length x width2) x 0.5 
* IR% = (1-TVt/TVc) x 100 
(wherein, TVt is average tumor volumes of the experimental group, 







4.2.6 Computing the stability and analyzing antibody-antigen 
interaction  
 
To analyze molecular interactions between the antibody and a 
HER2, the structural information of HER2 and hu4D5 was referred 
from the PDB (code: 1N8Z; web site: 
http://www.rcsb.org/pdb/home/home.do). To investigate effects 
of mutations in the antibody variable regions on stability, force 
field and charges were estimated using CHARMm module and 
Momany-Rone, respectively (Discovery Studio 3.5, Accelrys Inc, 
USA, http://accelrys.com/). Data of intraprotein interaction was 
obtained from Protein Interactions Calculator 
(http://pic.mbu.iisc.ernet.in/) and the binding energy between the 
antibody and HER2 molecule was calculated by the equation 1, as 
undermentioned. 
 
All the experiments were carried out on a 3.40 GHz Intel Core i7 
Quard-Core processor. Molecular modeling was performed using 
the Macromolecules modules on Discovery Studio 3.5 (Accelrys 
Inc.), and CHARMm (ver. 36.2) was used for energy minimization. 
 
Equation 1. Binding energy of antibody and antigen HER2 
 
∆G HER2:VH/VL binding energy = ∆G HER2/VH/VL energy – (∆G HER2 energy + ∆G 
VH/VL energy) 
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4.3 Results and Discussions 
 
4.3.1 Affinity determination of variants by SPR   
 
Binding affinities (KD) of selected variants to HER2 antigen were 
calculated from association rate constants (kon) and dissociation 
rate constants (koff) measured using BIAcore ™-T200 as koff/kon. As 
shown in Table 3-4 and Fig. 4-1, the KD value of parental antibody 
hu4D5 to antigen HER2 was 0.48 nM, and that of the D98W (in 
CDR-H3) variant modified from hu4D5 to antigen HER2 was 0.11 
nM, similar as described (Gerstner et al., 2002).  
Although binding affinities (KD) of most variants (AH16 A091, 
and etc.) were similar or decreased to that of parent hu4D5, on the 
other hand, the KD of AH06 was 60 pM and sharply showed 
improvement to 7.4-folds to that of parent hu4D5 (Fig. 4-1). This 
result indicates that the binding affinity of AH06 is remarkably 
increased.  
To investigate the effect of the other three changed residues, F100c, 
A101 and L102 in CDR-H3 of AH06 on the binding affinity to HER2, 
the “modified AH06 W98D” by substituting W at only one position 
Kabat #98 with D in CDR-H3 was additionally generated. As a 
result, the KD of the “modified AH06 W98D” was increased up to 
3.1-fold compared to that of hu4D5 (Table 3-4). 
Therefore, it was able to conclude that residues substitutions at 













Fig. 4-1. SPR binding analysis of isolated variants to immobilized human HER2-ECD. Antibody 
variants were injected at six different concentrations ranging from 100 nM, 20 nM, 4 nM, 0.8 nM, 0.16 nM, and 
to 0.032 nM over a surface on which 100 RU of HER2-ECD had been coupled. The parameters solved for each 
run are shown in Table 3-4 (Chapter 3). The KD of AH06 was 60 pM and sharply showed a 7.4-fold increase 
compared with that of parent hu4D5 (KD 0.48 nM). 
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M100c, D101 and Y102 of hu4D5 to W98, F100c, A101 and L102 of 
AH06 contribute to a considerable synergistic improvement of 
binding affinity to HER2. 
 
 
4.3.2 Domain specificity of variants against HER2 molecule  
 
To determine antigen binding epitope or domain on HER2, 
binding ELISA with a comparative antibody 2C4 (R&D system, 
USA) capable of binding to domain II of HER2 and the antigen 
ΔHER2-ECD-Fc (amino acid residues #22~584, R&D system) 
truncated in a part of domain IV and full HER2-ECD-Fc was 
analyzed. Since hu4D5 is known to bind to intact domain IV, and it 
cannot bind to domain IV-truncated antigen ΔHER2-ECD 
(Genentech Patent US6949245, 2005). On the other hand, the 
comparative test antibody 2C4 can bind to both antigens ΔHER2-
ECD and intact HER2-ECD and thus can be used for the 
comparative analysis. 
While antibody 2C4 could bind to both antigens ΔHER2-ECD and 
intact HER2-ECD, antibodies hu4D5, AH16 and A091 could not 
bind to ΔHER2-ECD. The binding ELISA indicates that variants 
AH06 and A091 is capable binding to domain IV of HER2 antigen, 




















Fig. 4-2. Domain specificity of the AH06 against HER2 molecule. 
AH06 is capable binding to domain IV of HER2 antigen, specifically, as 
similar to hu4D5. Indirect ELISA was performed with recombinant 
∆HER2-ECD or HER2-ECD fused with Fc as coating antigens. The 
∆HER2-ECD, which is a partially deleted form of domain IV consisting of 
562 amino acids from residue 22 to residue 584 of HER2 molecule were 
expressed in CHO-S cells and purified. The data are the average of 
duplicate determinations.  
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4.3.3 Cross-reactivity of variants to other receptor tyrosine 
kinases  
 
Antigenic cross-specificity or cross-reactivity of AH06 and A091 
was tested by using ELISA with HER family antigens (EGFR, HER2, 
HER3, HER4) and other receptor tyrosine kinases (RTK, such as 
PDGFRβ, VEGFR2, IGF1R, FGFR3 and HGFR). The variants AH06 
and A091 were not capable of binding to any other RTKs (EGFR, 
HER2, HER3, HER4, PDGFRβ, VEGFR2, IGF1R, FGFR3 and HGFR) 
































Fig. 4-3 A, B. Cross-reactivity of the isolated variants to HER 
family (A) and receptor tyrosine kinase family (B). AH06 was not 
capable of binding to any other RTKs (EGFR, HER2, HER3, HER4, 
PDGFRβ, VEGFR2, IGF1R, FGFR3 and HGFR) except only HER2 and 
were specific to only HER2 antigen.  
Indirect ELISA was performed with recombinant EGFR, HER2, HER3, 
HER4, PDGFRβ, VEGFR2, IGF1R, FGFR3 and HGFR as coating antigens, 
followed by treatment of the antibody variants and the antibodies 
binding to each coated receptor as positive controls. The data are the 
average of triplicate determinations.   
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4.3.4 Effect of variants on downstream signaling of HER2  
 
To determine the inhibitory mechanism of HER2 signaling by 
hu4D5 and AH06 variant, antibodies were treated in gastric cancer 
cell line NCI-N87. Protein levels including HER2, phosphorylated 
HER2 (pHER2), Akt, phosphorylated Akt (pAkt) and P27 were 
examined by Western blot analysis (Fig. 4-4). Phosphorylation of 
HER2 and AKT were inhibited without a change in protein 
expression of HER2 and Akt by treatment of hu4D5 as well as 
AH06.  
On the other hand, the expression level of the cyclin-dependent 
kinase inhibitor p27 was increased much more when cells were 
treated with AH06. These results suggest that AH06 antibody 
inhibits activation of the PI3K-Akt signaling pathways via HER2 
and induces cell death by increasing the expression of the p27 
similarly to the parent hu4D5. Thus, cell-context dependent 
induction of p27 might contribute to cellular susceptibility to AH06. 
Through the inhibition of signal transduction, the isolated 
antibody AH06 had a powerful anti-tumor effect in the in vitro, 





















Fig. 4-4. Effects of hu4D5 and AH06 on HER2 signaling.  
Protein levels of HER2, pHER2, Akt, pAkt and p27 were detected by 
western blot, after 10 g/ml of AH06 treatment to NCI-N87 gastric 
cancer cells. β-actin was also tested as a loading control.  
 
* Incubation time: HER2 (5 days), pHER2 (30 min), Akt/pAkt (16 hr), 






4.3.5 Antitumor efficacy of variants in vivo xenograft model   
 
To elucidate in vivo antitumor efficacy of antibody, in vivo 
xenograft was performed using breast cancer cells BT-474. Tumor 
volume was significantly decreased (p < 0.05) from days 7 to 42 
after administration of Herceptin (hu4D5) when compared with the 
vehicle group. AH16 and A091 significantly reduced (p < 0.05) 
tumor volume from days 24 to 42 and days 21 to 42, respectively, 
when compared with the vehicle control group (Fig. 4-5 A).  
 
Tumor weight was significantly reduced only in A091 group. 
Therefore, A091 caused tumor growth inhibition equivalent to that 
of hu4D5, as well as showed the stronger efficacy in terms of 
































Fig. 4-5. Antitumor efficacy of antibody in vivo BT-474 xenograft 
model. 
A. Antitumor efficacy of antibody in tumor volume.  




4.3.6 Computing and analyzing antibody-antigen interaction  
  
4.3.6.1 Binding analysis with binding energies and affinities  
 
To analyze binding modes and binding energies of 4 changed 
residues (W98, F100c, A101 and L102) of AH06 to its antigen HER2, 
molecular modeling methodology and the Equation 1 was used. 
The parent hu4D5 and a modified version of AH06 (AH06 D98), 
wherein W (Trp) was replaced with D (Asp) at 98 position in the 
CDR-H3 of AH06, were selected as references. 
 
Binding free energy was calculated using the Molecular Dynamics 
(CHARMM forcefield), but not the docking simulations 
considering protein-protein (HER2 and variants) interaction, and 
the binding structures between HER2 and variants (or hu4D5) were 
simulated based on PDB (code: 1N8Z). The binding free energy 
between HER2 and variants (or hu4D5) was calculated from the 
Equation 1.  
The relationship between the binding affinity and binding free 
energy is generally ∆G = -RT ln(KD) (Lee and Olson, 2006). 
Therefore, binding affinity is able to be calculated with binding free 
energy as follows. KD = e (-∆G/RT) (R: ideal gas constant, T: absolute 
temperature)  
The KD values of variants listed in Table 4-1B were experimental 
data obtained by SPR analysis (BIAcoreTM T200), and the ∆G values 
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listed in Table 4-1A and B were theoretical ones calculated from the 
Equation 1. Such comparison was carried out to see a correlation 
between binding affinity and binding free energy. 
 
Based on the calculation of binding energy, the association 
between binding energy and binding affinity depending on 
residues in CDR-H3 of AH06, hu4D5 and the “modified AH06” 
was analyzed. 
The residues W98, F100c, A101 and L102 in CDR-H3 of AH06 
were replace with D98, M100c, D101 and Y102, respectively, in that 
of hu4D5. AH06 had more a higher binding affinity for HER2 as 
well as lower binding energy, compared to hu4D5 (Table 4-1), 
suggesting that AH06 could bind to HER2 more stable than hu4D5. 
Next, it was investigated which ones among the 4 residues (W98, 
F100c, A101 and L102) of AH06, different from those of hu4D5, 
contributed to the improvements in terms of binding affinity and 
binding energy. 
 
Firstly, the only residual difference between AH06 and “modified 
AH06” is in position 98, W98 and D98, respectively. The binding 
affinity of AH06 to HER2 was stronger than that of “modified 
AH06” and the binding energy of AH06 was to some extent lower 
than that of “modified AH06” (Table 4-1).  
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hu4D5: CDR-H3 D98, M100c, D101, Y102,  
modified AH06: CDR-H3 D98, F100c, A101, L102 
AH06: CDR-H3 W98, F100c, A101, L102
 112 
Since 3 residues, F100c, A101 and L102, of CDR-H3 are present in 
both AH06 and “modified AH06”, it could be concluded that 
differences in binding affinity and binding energy of two 
antibodies are only determined by the residue W or D at position 
#98. The substitution with W at position 98 increased the binding 
affinity and decreased the binding energy, suggesting that W98 
plays a significant role in binding to HER2. 
 
Secondly, to evaluate roles of residues at the positions #100c, 101 
and 102 of CDR-H3, hu4D5 having M100c, D101 and Y102 residues 
was compared with the “modified AH06” having F100c, A101 and 
L102 residues. The binding affinity of “modified AH06” was about 
2-fold higher than that of hu4D5, however, unexpectedly there was 
no significant improvement in the binding energy of “modified 
AH06” compared to that of hu4D5 (Table 4-1). 
The analysis of binding affinity and binding energy of CDR-H3 
variants indicates that the 3 residues F100c, A101 and L102 of AH06 
can enhance binding affinity to HER2 (by additional hydrophobic 
interactions) about 3-fold, however, what exerts more influence is 
W98 of CDR-H3. 
Although this study did not calculate the binding energy of the 
“modified hu4D5 D98W” variant which the residue D at the 
position #98 of CDR-H3 of hu4D5 was substituted with W, the 
binding affinity of the “modified hu4D5 D98W” was about 3-fold to 
that of hu4D5 (Table 3-4), these results suggested that those 
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residues W98 and F100c, A101 and L102 of CDR-H3 of AH06 




4.3.6.2 Simulation of binding mode using molecular modeling 
analysis  
 
To elucidate the experimental data, the binding modes of hu4D5 
and AH06 to HER2 using molecular modeling was simulated and 
analyzed. The residues F100c, A101 and L102 of CDR-H3 of AH06 
were located in the region of VH-VL interface. Since these 3 residues 
were located several Å s apart from the HER2 residues (Fig. 4-6 A), 
it is unlikely that the residues directly interact with HER2 antigen. 
Therefore, they may indirectly contribute to improvement of 
binding affinity by influencing interaction between light and heavy 
chains of the antibody, rather than direct interaction with HER2 
molecule. 
 
It was simulated that there could be a direct hydrophobic 
interactions between the aromatic ring group of tryptophan residue 
(W98) of AH06 and the aliphatic group of isoleucine (I613) residue 
located in the domain IV of HER2 as well as the heavy and light 
chain hydrophobic interactions between the phenyl ring of F100c in 
CDR-H3 and the hydrophobic groups that is consist of Y36, P44 
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and F98 located in VL (Fig. 4-6 B). On the other hand, there was no 
significant interaction between the residue (D98) of hu4D5 and the 
aliphatic group of isoleucine (I613) residue located in the domain 
IV of HER2 (Fig. 4-6 C, D).  
 
In summary, computer modeling and simulation provided 
possible explanations for which residues influence improvement of 
binding affinity to HER2 and how they interact with other residues 
of antibody itself and with HER2. 
In addition, as Resi B. Gerstner et al. mentioned (Gerstner et al., 
2002), a clear role of W98 of CDR-H3 in HER2 binding is unclear. 
Here, this study provide a possible explanation for that using 










Fig. 4-6. Molecular interaction models of AH06 and hu4D5 complex 
with HER2. (A) A distance between three residues, F100c, A101 and 
L102 of modified AH06 (blue circle) and HER2 molecule (green). 
The residues F100c, A101 and L102 of CDR-H3 of AH06 were 
located in the region of VH-VL interface. The VH domain and VL 
domain are colored with red and blue, respectively. (B) Molecular 
interactions between VH and VL. The VH domain and VL domain are 
colored with pink and light blue. The residues F100c, A101 and 
L102 of CDR-H3 and Y36, P44 and F98 of VL were located in the 
region of VH-VL interface. It was simulated that there could be a 
direct hydrophobic interaction between the phenyl ring of F100c in 
CDR-H3 and the hydrophobic groups that is consist of Y36, P44 







Fig. 4-6. Molecular interaction models of AH06 and hu4D5 complex 
with HER2 (continued). (C) Ribbon model: The mutated region of 
variants is presented as a red square. (D) Surface model: The 
mutated region of variants is presented as a yellow square. Brown, 
hydrophobic; Blue, hydrophilic. It was simulated that there could 
be a direct hydrophobic interaction between the aromatic ring 
group of tryptophan residue (W98) of AH06 and the aliphatic 
group of isoleucine (I613) residue located in the domain IV of HER2 
as well as the heavy and light chain hydrophobic interactions by 




AH06 was the best candidate as a biobetter antibody that has an 
increase by 7.4-fold in binding affinity (KD: 60 pM) to HER2 
compared to hu4D5, respectively. 
AH06 specifically bound to domain IV of HER2 and did not have 
cross-reactivity with other receptor tyrosine kinases (RTK) such as 
HER1 (EGFR), HER3 and HER4, PDGFRβ, VEGFR2, IGF1R, FGFR3 
and HGFR. And also, AH06 decreased the level of phosphorylation 
of HER2 and AKT to a similar extent, but most of all, highly 
increased the overall level of p27 in gastric cancer cell NCI-N82 as 
compared to hu4D5, suggesting that AH06 could be a potentially 
more efficient therapeutic agent than parent hu4D5. 
To address how the binding affinity of AH06 to HER2 was 
enormously increased, binding energy calculation and molecular 
modeling stimulation were performed. As a result, it was indicated 
that the substitution of residues of CDR-H3 to W98, F100c, A101 
and L102 could stabilize binding of the antibody to HER2 and that 
there could be the direct hydrophobic interactions between the 
aromatic ring of W98 within AH06 and the aliphatic group of I613 
within antigen HER2 domain IV. And the substitution of the 
residues F100c, A101 and L102 of CDR-H3 within AH06 could 
result in the inter-chain hydrophobic interactions (not strong as 
that of W98) between the phenyl ring of F100c in CDR-H3 and the 
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hydrophobic groups that consist of Y36, P44 and F98 located in VL. 
Therefore, such two kinds of interactions exerted such interactions 
could have synergistic effects on improvement of binding affinity 

































Bioprocess Development of  




In order to release active antibodies to pharmaceutical market, it is 
required to establish a high-producing cell line and mass animal 
cell culture technology for achievement of the maximum cell 
growth and production. Thus, it is also required to develop 
screening system for selection of high-producing (expression) cell 
clones, study various media and additives, and optimize the 
production process.   
Among the variant such as AH06, AH16, and A091 discovered 
through the upstream antibody engineering technology and 
screening process (Refer to Chapter 3), firstly discovered AH16 
(IgG1) [Heavy chain, total 451 amino acid residues; VH, Kabat No. 
#1~113 (120 amino acid residues); CH1~3, #114~444 (331 amino 
acid residues); Light chain, total 214 amino acid residues; VL, Kabat 
No. #1~107 (107 amino acid residues); CL, #108~214 (107 amino 
acid residues); N-glycosylation at the position, N294] was chosen as 
a model antibody to establish and set-up the downstream 
bioprocess required to produce the antibody, and a series of 
bioprocess such as stable cell line development, culture media and 
additive screening, and purification process were performed (Fig. 
5-1).  
 
Therefore, as the first step, the development of stable cell line 
using suspension type of DHFR-deficient CHO DG44 cell is needed 
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In addition, selection and optimization of basal media and 
additives is also needed. In order to increase or maximize the 
antibody productivity, many companies such as BD Bioscience and 
SAFC have their own basal culture media and additives self-
developed through the culture media library or media formulation.  
In general, carbon sources, concentrated amino acids, vitamins, 
salts and minerals are included in supplement solutions, whereas 
lipids, hydrolysates and growth factors substances chemically 
undefined are not included. 
 
In the study on increment of productivity by screening of the 
media additives, there are a number of possible combinations of 
additives available, and so, the statistical analysis tools  such as 
Design-of-Experiment (DOE) are used to easily design and analyze 
media combinations and the result (Parampalli et al., 2007). To 
increase the productivity of anti-cancer antibody AH16-F1, the 
media and additive optimization is required through the screening 
of culture media and their additives for the AH16 producing stable 
cell line. Therefore, to determine the optimal media and additives, 
screening with 5 commercial basal media and 10 supplements 
(additives) was performed.  
 
As next step, in order to purify AH16 from the culture fluids and 
optimize the purification process, after testing resins from the 
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major manufacturers under the same conditions, the proper Protein 
A resin was selected based on purity, yield, quantity of leached 
Protein A, prices and ease of CIP (cleaning-in-place). Next step, SP 
Sepharose HP resin was used for capturing step to establish a non-
Protein A-based process. The sulfopropyl (SP) functional group is a 
strong cation exchanger in the resin. Using this cation exchange 
chromatography, we tried to purify the target protein AH16 can be 
efficiently separated from impurities such as HCP and HCD. 
 
The study on analysis and evaluation for characterization of API 
(active pharmaceutical ingredient) and establishing the physico-
chemical and biological criteria of the novel antibody as API 
produced through the bioprocess and clinically used is very 
important and absolutely necessary as a mean of quality 
management to monitor and control clinical efficacy and side 
effects. Therefore, API of AH16 produced through the bioprocess 










5.2 Materials and Methods  
 
5.2.1 Construction of expression vector 
 
An expression vector named pCLS05 (Korean Patent Application 
No. 10-2011-0056685) was invented in order to produce a Herceptin 
variants, AH16 from CHO DG44 cell. Heavy and light chain genes 
were inserted in the multiple-cloning site (MCS) of the vector and 
expressed under the control of a CMV promoter. Also, a scaffold 




5.2.2 Transfection of CHO DG44 cells using pCLS05AH16F1 
vector   
 
CHO DG44 cells were purchased from Life Technology (USA) 
(Cat. No. 12609-012, Lot No. 363938) and used as a parental cell line 
for AH16 drug substance production. CHO DG44 is a stable 
aneuploid cell line established from a Chinese Hamster's ovary 
(Tjio and Puck, 1958) and dihydrofolate reductase (DHFR)-deficient 
(Urlaub et al., 1983; Kaufman et al., 1985; Werner et al., 1998).  
Transfection of CHO DG44 cells was performed as following 
methods using an electroporation. Approximately 24 hours before 
transfection, DG44 cells were inoculated at 3 x 105 cells/ml in an 
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125-ml flask containing 30 ml DG44 medium. The flasks were place 
on an orbital shaker platform rotating at 110 rpm at 37°C, in a 
humidified 5% CO2. At that time, cells were measured using 
tryphan blue and maintained at least 95% cell viability for high 
transfection efficiency.  
On the day of transfection, DG44 cells were diluted at 1 x 107 
cells/ml in 0.5 ml CD OptiCHO. Thirty g pCLS05AH16F1 were 
added into the cells. The DNA and cells were mixed gently and 
transferred to a sterile electroporation cuvette. Transfection was 
performed using the Gene Pulser Xcell electroporation system (Bio-
Rad, USA). The condition was 150 voltages and 950 F capacitance. 
The transfected cells were transferred to a T75 flask containing 
DG44 medium and cultured for 3 days. 
 
 
5.2.3 Selection of stable transformants producing AH16 
 
After 3 days of transfection, transformants were measured cell 
viability and added 10 ml of the OptiCHO media every 2~3 days. 
The cells were maintained by adding 10ml of the OptiCHO media 
every 2~3 days, and the cell viability was assessed. When the cell 
culture media in the T75 Flask reached 40 ml, it was replaced with 
20 ml of fresh media. This procedure was repeated until cell 
viability reached between 90~100%. 
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5.2.4 Selection of single colonies using ClonePix  
 
After selection, stable pool were inoculated at 5 x 106 cells in the 6-
well plate containing CloneMedi-CHO DHFR semi-solid media. 
The cells were cultured for 2 weeks and isolated single colonies 




Table 5-1. ClonePix picking condition. 
Name Expression 
Edge Excluded IF Edge Excluded = True 
Too Big IF Total Area >= 0.7 
Too Small IF Total Area <= 0.05 
Irregular 1 IF Compactness <= 0.45 
Irregular 2 IF Axis Ratio <= 0.45 
Proximity IF Proximity <= 0.4 
Low FITC 
IF [FITC 1s] Exterior Mean Intensity <= 1,470.970  
AND [FITC 1s] Interior Mean Intensity <= 210 
Accept Anything else 
 
 
5.2.5 Scale-up of culture for selecting clones 
 
In order to select the top 20% of clones in terms of AH16 
expression, a quantitative ELISA was performed with the cell 
culture supernatants. The selected cell clones were transferred to a 
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24-well plate and cultured. When the cells were cultured to 90% 
confluent in the well, the productivity was estimated by ELISA. 
The top 15% of the clones with AH16 expression were selected and 
inoculated at 2 x 10⁵ cells/ml in 125 ml Erlenmeyer flask containing 
30 ml CD FortiCHO media with 500 g/ml Geneticin, 4 mM L-
glutamine. The flasks were place on an orbital shaker platform 
rotating at 110 rpm at 37°C, in a humidified 5% CO2.  
After 3 passages, both of cell growth and productivity were 
measured. In order to select clones for MTX amplification, specific 
growth rate () and specific product rate (q) (Derek et al., 2007) 
were calculated. 
 
The specific growth rate () and the specific productivity (q) were 
calculated as follows.   
Specific growth rate () = (ln X2 - ln X1)/day 
(wherein, X1 is viable cell density at seeding time and, X2 is viable 
cell density at sampling time, and D (day) is time of sampling.) 
Specific productivity rate (q) = PCD (pg/cell/day)  
= ΔTiter/ΔIVC x 106 
(wherein, ΔIVCD (integral viable cell density) (unit: cells x 
day/ml) = (X2 - X1)/(ln X2 - ln X1) x day.  
ΔTiter means productivity of products. X1 is viable cell density at 




5.2.6 MTX amplification 
 
After clonal selection, the cells were diluted at 3 x 105 cells/ml in a 
125-ml Flask containing 30 ml CD Opti CHO media with 20 nM 
MTX and 500 g/ml Geneticin. Flasks were placed on an orbital 
shaker platform rotating at 110 rpm at 37°C, in a humidified 5% 
CO2. The cell culture media were exchanged every 3 days until cell 
viability is between 90~100% and the media volume was kept 
above 30 ml.  
Once the first round of MTX selection resulted in higher levels of 
protein expression and better viability, the stable cells were 
inoculated at a final concentration of 2 x 105 cells/ml in a 125-ml 
flask containing 30 ml of CD Opti CHO media with 500 g/ml 
Geneticin and 8 mM L-glutamine, and the culture media were 
harvested for ELISA determination of product titer after 11 days of 
incubation.  
 
Based on productivity and quality, additional amplifications were 
performed after gene amplification using 20 nM MTX. The cells 
selected in the first round of amplification were inoculated at 3 x 
105 cells/ml in growth media with 80 nM MTX. The media were 
exchanged every 3~4 days until cells viability were 90%.  
After recovery, the cells were diluted at 2 x 105 cells/ml in CD 
Opti CHO media with 500 g/ml Geneticin, 8 mM L-glutamine 
and maintained for 12 days to measure clonal productivity by 
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using IgG ELISA. The second amplification with 80nM MTX was 
terminated and followed additional amplifications with increasing 
MTX concentrations (160 nM, 320 nM). To estimate an output of the 
cells, ELISA was performed after all round of amplification.  
After MTX amplification, the subcloning and scale up process 
were performed as described previously. Considering specific 
growth rate (μ) and specific product rate (q), the final clone was 
selected as a producer stable cell line.   
 
 
5.2.7 Quantification of antibody AH16F1 by ELISA 
 
The wells of microtiter plates were coated with goat anti-human 
IgG-Fc antibody diluted at a 1:200 ratio in coating buffer. After 
saturation with 1% BSA, both of sample diluted in PBS and Human 
reference Serum diluted in PBS were added to the well. After 
washing, goat anti-Human IgG-Fc-HRP antibody (Bethyl, A80-104P, 
1 mg/ml) diluted at a 1:100,000 ratio in 1% BSA/TBST was added 
and kept. Finally, TMB solution was added into the well and the 
color was developed in dark. The reaction was stopped by adding 2 
N of sulfuric acid, and absorbance was measured at 450 nm using 





5.2.8. Comparison of 5 commercial media for the screening of 
basal medium 
 
Five commercial basal media 3 chemically defined (CD) media 
family, CD FortiCHO (Invitrogen Cat. A11483-01) and Power 
CHO2CDM (Lonza Cat. BE12771Q), ProCHO 5 (Lonza Cat. BE12-
766Q), and 2 serum-free media family, SFM4CHO (HyClone, Cat. 
SH30548.02) and UltaCHO (Lonza, Cat. 12-724Q) were used to 
screen the optimal basal medium for the AH16-producing stable 
cell line.  
 
 
5.2.9 Cell culture and assessment for media screening 
 
AH16F1-3-14-80-26 cell line expressed AH16 was inoculated at the 
final concentration of 2 x 105 cells/ml in a 125-ml Erlenmeyer flask 
containing 25 ml of growth medium supplemented with 4 mM 
glutamine. 
Evaluations for the selection of basal medium were based on the 
cell survival and productivity. After 7 days of cell culture, the cell 
number and survival rate were measured by trypan blue staining, 
the culture fluid was collected and the concentration of antibody in 




5.2.10 Measurement for the effect of a single additive 
 
Ten kinds of a single additive, HYPEP 5603, HYPEP 7504, HYPEP 
1510, HYPEP 4601, Cotten CNE 50M, TC yeastolate, Soytone, Sheff-
CHO Plus ACF, Cell Boost6 and Cell Boost5 were tested to screen 
basal additives. The 10x concentrates of each additive were 
prepared in PowerCHO 2CDM media, and they were diluted to 1X 
concentration and used in main culture experiment (Table 5-2). 
To compare the effects of 10 additives for cell culture, each 10 
kinds of media additives and the control group (e.g., no additives 
were added to basal medium, either PowerCHO 2CDM or 
FortiCHO in a 125-ml Erlenmeyer flask, resulting in total 22 
experimental groups. Four mM of glutamine was added to each 
basal medium, and the AH16 producing stable cell was inoculated 
to be a concentration of 2 x 105 cells/ml to in a total volume of 25 
ml.  
Evaluations for the selection of basal medium were based on the 
cell survival and productivity. Seven and 10 days after the cell 
culture started, the cell number and survival rate were measured 
by trypan blue staining, and the concentration of antibody was 







Table 5-2. Concentrates of media additives for AH16F1-3-14-80-26 
cells. 
Additives (Abbreviation) Conc. of 10X concentrates (g/L) Test conc. (g/L) 
HYPEP 5603 (5603) 50 5 
Soytone (SOY) 50 5 
HYPEP 7504 (7504) 50 5 
Cotten CNE 50M (CNE) 50 5 
Sheff-CHO Plus ACF  
(Plus PF) 
50 5 
HYPEP 1510 (1510) 50 5 
HYPEP 4601 (4601) 50 5 
TC yeastolate (TC) 50 5 
Cell Boost5 (C.B 5) 50 3.5 
Cell Boost6 (C.B 6) 50 3.5 
 
 
5.2.11 Determination of a ratio for the composition of media 
additives  
 
To test the mixture ratio of 3 kinds of single additives (HYPEP 
4601, Sheff-CHO Cell Boost5 ACF and Plus) selected from the 
culture test earlier, it was designed as Table 5-3. 
According to the design of the additives mixture ratio (as Table 5-
3), each 10 combinations were added to basal medium, either 
PowerCHO 2CDM or FortiCHO in a 125-ml Erlenmeyer flask, 
resulting in total 20 experimental groups. The AH16 producing 
stable cell was inoculated to be a concentration of 2 x 105 cells/ml 
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in a total volume of 25 ml.  
Evaluations for the selection of media additives were based on the 
cell survival and productivity. After 7, 10 and 12 days of the cell 
culture, the cell number and survival rate were measured by trypan 
blue staining, and the concentration of antibody was measured by 
IgG ELISA method as described above.   
Ten cultured fluids of 12-day in PowerCHO 2CDM media were 
filtered with 0.2 m filter, and the concentrations of the antibody 
IgG was measured by using Protein A-HPLC. And the optimal 
mixture ratio of additives was determined using the JMP program 
for mixture analysis based on the measured antibody 
concentrations.  
 
Table 5-3. Mixture ratio of media additives for AH16F1-3-14-80-26 
cells. 
Flask No. HYPEP 4601 (g/L) Sheff-CHO Plus ACF (g/L) Cell Boost5 (g/L) 
1 5  0 0 
2 0 5 0 
3 0 0 3.5 
4 2.5 2.5 0 
5 0 2.5 1.75 
6 2.5 0 1.75 
7 1.7 1.7 1.2 
8 2 2 0.7 
9 2 1 1.4 
10 1 2 1.4 
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5.2.12 Determination of schedule for addition of media additives 
mixtures 
 
The schedule test for addition of additives was performed in the 
conditions as follows (Flask No. 1: Only once at 3 days after 
seeding; Flask No. 2: Three times at 3, 6, 9 days after seeding; 
Flask No. 3: Three times at 4, 7, 10 days after). Four mM of 
glutamine was added to the PowerCHO 2CDM basal media, the 
recombinant human albumin was added at a final concentration of 
250 mg/L on 7 days after culture. The AH16-producing stable cells 
were inoculated to be a concentration of 2 x 105 cells/ml in a total 
volume of 100 ml in a 500-ml Erlenmeyer flask. After 3 days of 
culture, the cell concentration, survival rate and metabolism 
analysis were periodically checked, and the glucose concentration 
of the culture was maintained to more than 2 g/L by adding 
glucose stock solution when the glucose concentration was lower 
than 3 g/L.   
 
 
5.2.13 Samples for purification, resins, column, equipment, and 
reagents (Protein A process) 
 
Samples for purification were 80 ml of the perfusion culture fluid 
of an AH16-F1 cell line, and the lists of resins, column, equipment, 
instruments and reagents were as follows. 
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• Resins used for Protein A resin screening test: MabSelect Xtra 
(GE), MabSelect Sure (GE), MabSelect Sure LX (GE), ProSep 
Ultra Plus (Merck Millipore), Absolute High Cap Protein A 
(Novasep), Protein A ceramic Hyper D_F (Pall). 
The resins were prepared in a 5 × 50 (1 ml) column using 
column packing ATOLL's service.  
• Columns used for Protein A-based process study: MabSelect 
Xtra (GE) 5 ml prepacked column, Q Sepharose FF (GE) 5 ml 
prepacked column, SP Sepharose HP (GE) 5 ml prepacked 
column. 
• Equipments and instruments: AKTA purifier(GE), AKTA 
Avant 150 (GE), conductivity meter(IsTek), pH meter (Mettler), 
stirrer (corning), balance (Mettler) 
• Reagents: 10X PBS pH7.4 (Gibco), citric acid (Sigma), sodium 
citrate (Sigma), Trizma base (Merck), sodium hydroxide 
(Merck), sodium di-hydrogen phosphate monohydrate (Merck), 
ethanol (Merck), di-sodium hydrogen phosphate dihydrate 
(Merck), sodium chloride (Merck) 
 
 
5.2.14 Small-scale purification using Protein A and non-Protein 
A resin (column)  
 
Since a pre-run procedure is generally recommended, each 
column was pre-run prior to the sample loading, as the real process.  
 136 
The same purification method was applied to 6 proteins A columns. 
A flow rate was 1 ml/min and steps for purification were as 
follows. 
Step 1. Equilibration: 10 CV (column volume: packed resin 
volume) of 1X PBS (pH 7.4) was applied to equilibrate the 
column. 
Step 2. Sample loading: Using the AH16-F1 stable cell line, 
loading perfusion culture fluid 80 ml. 
Step 3. Washing unbound proteins: The column was washed with 
20 CV of PBS (pH 7.4) to remove non-specifically bound 
compounds. 
Step 4. Gradient elution: [A buffer: 1X PBS pH 7.4 /B buffer: 100 
mM citrate pH 3.0] A gradient of B buffer to A buffer in 
10 CV was applied to elute the target protein in fractions. 
3.5 ml, corresponding to one-fourth volume of the elution 
fraction, of 1M Tris-HCl, pH 9.0 was added to each 
collection tube prior to elution to immediately neutralize 
the elution fractions. 
Step 5. Hold: 5 CV of 100 mM citrate (pH 3.0) was applied to the 
column in order to elute any remaining residual target 
protein. If elution peak tailing appeared, put holding step 
and prevent loss of samples, but in this experiment peak 
tailing was not observed.  
Step 6. Re-equilibration/CIP/storage: 10 CV of PBS, pH 7.4 was 
applied in order to re-equilibrate the column, and CIP 
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was performed as described in the manual. The column 
was filled with the storage buffer and stored at 4°C.  
 
 
5.2.15 Analysis of intermediates and final purified products 
 
Purity of the sample during the purification steps was analyzed by 
SDS-PAGE, SEC-HPLC, and UV absorption spectrometry (at 280 
nm). For SDS-PAGE analysis, NuPAGE 3~12% Bis-Tris gel (1.0 mm, 
10 well; Invitrogen) was used. After loading 10 g of proteins onto 
each well, the gel was run for 60 minutes at 150 V (constant 
voltage) under reducing and non-reducing conditions.  
Absorbance of the protein was measured at 280 nm using Gen5 
2.00 (BioTek, USA), and the protein concentration was calculated 
using the mass extinction coefficient for IgG. 
 
 
5.2.16 Structural analysis and identification tests 
 
The “Specifications and Analytical Procedures” and its analytical 
test items for characterization and analysis of AH16 API were 





Table 5-4. The “Specifications and Analytical Procedures” items 
and methods.  
Test item  Purpose  
Test methods and 
Equipment 
References  
1. Appearance - N.A.  
2. pH measurement 
General test for 
“measurement of pH” 
(Korean 
Pharmacopoeia) 
3. Endotoxin measurement 
LAL (Limulus Amebocyte 
Lysate) test 
- Endosafe® -PTSTM Kit  
(Charles river, PTS 100) 
(USPC, 2005; 
Yamamoto et al., 
2000) 
4. Identification test (Structure analysis & identification) 




Peptide mapping analysis  
- HPLC (Waters, e2695)  













3) SDS-PAGE Identification 
SDS-PAGE 
- XCell SureLock Mini-Cell  
(Invitrogen, E10001) 
 
5. Purity test    







Coulter, PA 800 plus) 
(Beckman 
Coulter, 2011) 




SE-HPLC (Waters, e2695)  








CEX-HPLC (Waters, e2695) 
- Column (Dionex, ProPac  
WCX-10 Analytical) 
(Harris et al., 
2001; Moorhouse 
et al., 1997) 
4) Host cell protein 
(HCP) 
Host cell derived 
peptide analysis 
ELISA  
(BioTek, Microplate reader) 
 
5) Host cell DNA 
(HCD) 
Host cell derived 
DNA analysis 
ELISA (Molecular Devices, 
FlexStation 3 Benchtop) 
 
6. Contents test 
Quantity of the 
active ingredient 
































5.3 Results and Discussion  
 
5.3.1 Construction of the AH16 expression vector 
 
An expression vector named pCLS05AH16F1 was invented in 
order to produce HER2 antibody AH16, a biobetter of Herceptin. In 
order to enhance productivity, two copies of CSP-B 5' SAR were 
inserted into the vector consisting of a CMV promoter, a dhfr gene, 
a neomycin resistance gene, a pUC origin and an ampicillin 
resistance gene. The dhfr gene makes the cells transfected have 
resistance to MTX in culture medium and then helps the cells 
survive and the target gene within the vector be amplified in 
chromosomes. 
To ensure that an accurate manufacturing of the pCLS05AH16F1, 
enzyme mapping was performed by using enzymes such as Bam 


























5.3.2 Selection of single colonies using ClonePix  
 
After isolation of stable clones, the cells were diluted to 5 x 106 
cells/well in the 6-well plate containing CloneMedi-CHO DHFR 
semi-solid media. After 2 weeks, the cultured cells were observed 
under a microscope and picked using ClonePix. Sixty eight clones 
were picked up among the 14,812 clones based on FITC level. The 






Table 5-5. Summary of clone picking. 
Name Count Expression 
Edge Excluded 6,207 IF Edge Excluded = True 
Too Big 0 IF Total Area >= 0.7 
Too Small 8,235 IF Total Area <= 0.05 
Irregular 1 196 IF Compactness <= 0.45 
Irregular 2 57 IF Axis Ratio <= 0.45 
Proximity 36 IF Proximity <= 0.4 
Low FITC 13 
IF [FITC 1s] Exterior Mean Intensity <= 1,470.970 
AND [FITC 1s] Interior Mean Intensity <= 210 
Accept 68 Anything else 
Sum 14,812  
 
 
Fig. 5-3. Ranking plot in ClonePix. 
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5.3.3 Selection of amplified clones using MTX 
 
The picked 68 clones were cultured for 2 weeks and the growth 
media were added. To estimate productivity of the clones, ELISA 
was performed. As a result (Table 5-6), the top 20% of clones were 
transferred to 24-well plates and cultured. When the cells in the 
well reached 90% confluent, ELISA was performed with the cell 
culture media to determine productivity (Table 5-7). Based on the 
productivity, the top 15% of the clones were selected and cultured 
in 6-well plates.  
When the cells were cultured to 90% confluent in the well, the 
media were collected for ELISA determination of productivity. 
High expressed 15% clone were selected in the group (Table 5-8), 
they were inoculated at 3 x 10⁵ cells/ml in 125-ml flasks containing 
30 ml CD FortiCHO media with 500 g/ml Geneticin, 4 mM L-
glutamine. The cells were incubated at 37°C, in 5% CO, with orbital 
shaking at 110 rpm and the specific growth (μ) and productivity (q) 
(Table 5-9) were measured. AH16F1-3-11 and AH16F1-3-14 clones 


























14 1.70  1566.59 90 % 7 0.18  2107.69 10 % 
3 0.94  2651.42 90 % 30 0.15  512.566 90 % 
2 0.93  3329.29 80 % 49 0.15  121.207 50 % 
24 0.89  733.195 10 % 48 0.13  125.539 90 % 
4 0.88  2343.42 90 % 22 0.11  760.974 40 % 
9 0.79  1731.36 5 % 58 0.10  66.481 20 % 
13 0.76  1600.74 10 % 46 0.10  162.931 10 % 
20 0.67  819.171 20 % 43 0.10  258.918 10 % 
5 0.60  2335.93 40 % 6 0.09  2331.56 10 % 
11 0.56  1668.25 5 % 36 0.09  379.492 5 % 
29 0.46  533.723 30 % 34 0.09  442.091 5 % 
17 0.41  1019.13 20 % 62 0.08  43.032 5 % 
47 0.38  162.618 30 % 45 0.06  193.188 5 % 
31 0.32  471.043 10 % 63 0.06  42.36 10 % 
10 0.26  1680.49 30 % 35 0.06  409.971 20 % 
21 0.24  765.695 90 % 55 0.05  79.435 10 % 
28 0.22  604.682 20 % 57 0.05  75.473 10 % 
12 0.22  1643.07 10 % 23 0.04  741.56 30 % 
15 0.21  1519.55 20 % 53 0.03  100.423 50 % 
19 0.19  826.292 20 % 68 0.02  24.119 20 % 
32 0.19  467.444 40 % 41 0.02  276.487 90 % 
59 0.19  59.919 80 % 42 0.02  268.561 5 % 
52 0.19  109.98 90 % 26 0.02  653.685 10 % 
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AH16F1-3-11 129.75  100 AH16F1-3-39 6.24  90 
AH16F1-3-14 106.70  100 AH16F1-3-21 5.23  10 
AH16F1-3-20 46.24  50 AH16F1-3-3 4.69  50 
AH16F1-3-1 35.99  80 AH16F1-3-2 3.70  30 
AH16F1-3-31 20.21  60 AH16F1-3-12 3.43  50 
AH16F1-3-30 15.94  60 AH16F1-3-22 3.01  20 
AH16F1-3-59 13.42  90 AH16F1-3-32 2.67  30 
AH16F1-3-24 12.64  50 AH16F1-3-34 1.66  80 
AH16F1-3-44 11.30  90 AH16F1-3-4 1.59  40 
AH16F1-3-9 11.29  80 AH16F1-3-42 0 20 
AH16F1-3-5 10.44  10 AH16F1-3-68 0 20 
AH16F1-3-48 10.17  90 AH16F1-3-5 0 10 
AH16F1-3-49 10.10  90 AH16F1-3-21 0 10 
AH16F1-3-16 9.97  100 AH16F1-3-22 0 10 
AH16F1-3-52 9.41  40 AH16F1-3-30 0 20 
AH16F1-3-53 8.08  40 AH16F1-3-32 0 10 
AH16F1-3-13 8.06  80 AH16F1-3-41 0 100 









Table 5-8. ELISA for IgG from cell culture supernatants in 6-well 
plates. 
Sample IgG conc. (g/ml) Well confluency (%) 
AH16F1-3-11 105.50  100 
AH16F1-3-14 102.20  100 
AH16F1-3-3 92.49  100 
AH16F1-3-59 48.28  100 
AH16F1-3-48 32.67  100 
AH16F1-3-49 27.22  100 
AH16F1-3-52 20.40  100 










Cell conc. (cells/ml) 
μ 
q (pg/cell/day) 
Day 0 Day 12 Δtiter/ΔIVC 
AH16F1-3-11 150.0  3.0x105 4.3x106 0.24  9.08  




5.3.4 MTX amplification 
 
AH16F1-3-14-11 and AH16F1-3-14 clones were diluted at 3 x 105 
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cells/ml in 125-ml Flasks containing 30 ml of CD Opti CHO media 
with 500 g/ml Geneticin and 20 nM or 80 nM MTX. The flasks 
were placed on an orbital shaker platform rotating at 110 rpm at 
37°C, in a humidified 5% CO2. After MTX amplification, the media 
were harvested and ELISA was performed for comparison of 
productivity. AH16F1-3-14 with 80nM MTX showed a higher 
production (Table 5-10). Therefore, AH16F1-3-14-80 clone was 
selected for further subcloning.   
 
 
Table 5-10. Comparison of antibody productivity of clones 
amplified with MTX (IgG conc.: g/ml). 
Clone no. 0 nM 20 nM 80 nM 
AH16F1-3-11 150.5 162.9 101.9 
AH16F1-3-14 183.75 - 198.4 
 
 
5.3.5 Selection of single clone using ClonePix 
 
After selection, AH16F1-3-14-80 cells were inoculated at 1 x 103 
cells per well in 6-well plates containing CloneMedi-CHO DHFR 
semi-solid media. The cells were cultivated for 2 weeks and single 
colonies were isolated using ClonePix. Eighty cells were picked up 
among 18,373 cells based on FITC level (data not shown).  
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5.3.6 Selection of stable clone AH16F1-3-14-80-23 
 
Eighty clones were cultured in 96-well plates containing the 
growth media for 2 weeks. In order to measure the antibody titers 
in 96-well plates, ELISA was performed with the media (Fig. 5-4). 
The clones were scaled up from 24-well to 6-well plates and 125-ml 
flasks. Each of the steps, the productivity was measured using IgG 
ELISA (Fig. 5-5, 6, 7). After comparing antibody titers, 4 top 
producing antibody clones (AH16F1-3-14-80-13, 15, 17 and 26) were 
selected. Both of the specific growth (and the specific 
productivity (q) were measured to select the final clone among the 
4 clones (Fig. 5-8, 9). Based on the result, AH16F1-3-14-80-26 was 













Fig. 5-4. AH16F1 antibody titers in 96well plates. 
 
 
Fig. 5-5. AH16F1 antibody titers in 24-well plates. 
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Fig. 5-6. AH16F1 antibody titers in 6-well plates. 
 
 














Table 5-11. Comparison of specific growth rate (μ) and specific 
productivity rate (q, pcd) of selected 4 clones.  
Clones μ  q (pg/cell*day) 
AH16F1-3-14-80-13 0.42  10.11  
AH16F1-3-14-80-15 0.37  13.40  
AH16F1-3-14-80-17 0.42  14.99  





Fig. 5-10. Cell density and viability of the selected 4 clones during 
culture: Comparison of viability and the number of cells 




5.3.7 Assessment of the stability of the cell line producing AH16 
over passages 
 
To assess stability of the selected “stable cell line”, AH1F1-3-14-80-
26 expressed AH16F1, the productivity and growth rate were 
measured through long-term culture (15 passages) as described 
above.  
The ELISA was performed for measuring antibody titers after 10, 
11 and 12 days of culture. In the same way as above, the antibody 
titers ranged from 180 g/ml to 245 g/ml through 15 passages. 
The stably maintained antibody titer indicated the long-term 
stability of the cell clone (Fig. 5-11).  
 
To determine the growth curve (or stability) of the stable cell clone 
AH16F1-3-14-80-26 during cell passages, both of viability and 
concentration of the cells were measured using trypan blue. By the 
results, the growth curve and survival rates at passage number 1, 5, 
10, and 15 were very similar (Fig. 5-12).  
Also, the antibody production at the 10, 11, and 12 days of 1~15 
passages were consistently maintained to 180~220 g/ml. 
Therefore, the antibody production and growth rate had been 
consistently maintained, which verified stability of the clone. 
Therefore, the AH1F1-3-14-80-26 clone can be suitable for large-





Fig. 5-11. IgG productivity of the stable cell line AH16F1-3-14-80-26 










Fig. 5-12. The growth and viability curves of the stable cell clone 
AH16F1-3-14-80-26. 
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5.3.8 Selection of the basal media for the culture of the stable 
cell AH16F1-3-14-80-26 
 
Based on IgG productivity at 7 days of culture, the PowerCHO 
2CDM was selected as a basal medium among 5 basal media as 
shown in Fig. 5-13. However, other tests such as determination of 
mixture ratio of additives were compared to the results from using 











5.3.9 Effects of single additives for AH16 production in basal 
media PowerCHO 2CDM 
 
Cell growth, survival rate and AH16 productivity were assessed 
through the screening of 10 additives in basal media PowerCHO 
2CDM, the additives Cell Boost5 (abbreviated as C.B 5) in 
PowerCHO 2CDM media showed the best performance in the 
maintenance of cell growth and viability of the stable cell line 
AH16F1-3-14-80-26 clone as well as in the production of the AH16 
antibody (data not shown). 
 
 
5.3.10 Productivity of media additives mixture in basal media 
PowerCHO 2CDM at 12 days 
 
AH16 productivity of 12 days was determined using Protein A-
HPLC to screen media additives mixture in basal media 
PowerCHO 2CDM. The additives mixture combination No. 2 
(abbreviated as Combi. 2 : HYPEP 4601 zero g/L, Sheff-CHO Plus 
ACF 5 g/L, Cell Boost5 zero g/L) and No.5 (abbreviated as Combi. 
5 : HYPEP 4601 zero g/L, Sheff-CHO Plus ACF 2.5 g/L, Cell Boost5 





Table 5-12. IgG productivity related to the ratio of media 















5.3.11 Determination of the ratio for combination of additives in 
basal media PowerCHO2 
 
AH16 productivity of 10 arbitrarily designed media additives 
mixture combination in basal media PowerCHO 2CDM is as shown 
in Table 5-12. However, the best optimal combination ratio that was 
not designed yet, the best optimal combination ratio was calculated 
by statistical analysis program JMP (SAS Co., USA) using the 
productivity data measured by Protein A-HPLC at 12 days.  












The best optimal combination ratio of 3 media additives was 
determined as HYPEP 4601 : Sheff-CHO Plus : Cell Boost5 = 
0.0024 : 0.7290 : 0.2685. So, it could be converted as HYPEP 4601 : 
Sheff-CHO Plus ACF : Cell Boost5 = 0.0012 g/L : 3.6 g/L : 1.3 g/L 






















5.3.12 The schedule determination for addition time  
 
The productivity of AH16 was obtained to approximately 1.3g/L 
in the flask culture when the optimized combination mixture of 3 
additives (HYPEP 4601, Sheff-CHO Plus ACF, Cell Boost5) 
calculated by JMP analysis was added at 3, 6, and 9 days of culture 
and when the glucose concentration in culture was kept to more 













Fig. 5-15. IgG productivity depending on the addition of the 
media complex additives at 3, 6, 9 days after 
inoculation of AH16-producing stable cells in 
PowerCHO 2CDM. (1, at 3 days; 2, at 6 days; 3, at 9 
days)  
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5.3.13 Summary of Protein A resin selection on a small scale 
 
To select a more appropriate Protein A resin, 6 kinds of Protein A 
column were compared with purity and ligand leaching, MabSelect 
Sure and MabSelect Sure LX of GE healthcare showed the best 
performance (Table 5-13).  
 
 
Table 5-13. Comparison summary of Protein A-based resins. 
 












1   MabSelect Xtra 97.3 (4) 19.2 (2) 88.2 (1) Medium 
2   MabSelect Sure 98.3 (1) 8.1 (1) 81.7 (4) High 
3   MabSelect Sure LX 98.2 (2) 19.8 (3) 81.3 (6) High 
4   Prosep Ultra Plus 96.3 (6) 70.8 (5) 83.2 (2) Low 
5   Absolute High Cap 96.6 (5) 67.5 (4) 83.0 (3) Medium 
6 
  Protein A Ceramic 
HyperD_F 
97.4 (3) 968.4 (6) 81.6 (5) Medium 






5.3.14 Evaluation of process yield and purity in Protein A-based 
small-scale purification study 
 
The process was validated with culture fluids from three different 
cell lines. The products purified using MabSelect Sure column were 
diluted and loaded onto the second (Q Sepharose FF) and the third 
(SP Sepharose HP) columns connected in series. After loading, the 
second column was removed and purification was performed. The 
average yield and purity through 3 step purification processes were 
of 93.8% and 99.9%, respectively (Table 5-14), indicating a very 
effective purification process was developed.  
 
 
Table 5-14. Protein A-based purification process and evaluation 
of yield and purity. 
 






















Hu 1-8-80-9   0.194 40 7.8 0.479 15 7.2 92.6 99.93 
Hu 1-8-80-28   0.305 40 12.2 0.764 15 11.5 93.9 99.86 
Hu 1-8-80-29  0.384  40 15.4 0.972 15 14.6 94.9 99.89 
* IgG amount (mg): estimated by Protein A HPLC 
** Purity (%): analyzed by SEC-HPLC 
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5.3.15 Analysis of non-protein A-based small-scale purification 
process  
 
Non-protein A-based purification process using SP Sepharose HP 
column was evaluated by SEC-HPLC (purity was 97.5%, data not 
shown) and the final yield. The final yield in the first step (capture) 
using SP Sepharose HP column was 99.4% (Table 5-15).  
In general, it is known that non-protein A-based purification is 
inferior to protein A-based process on the yield and purity, but in 
this study, the first step (capture) in purification processes was able 
to be established with high purity and high efficiency.  
 
 
Table 5-15. Analysis of small-scale non-protein A-based 









Loading 0.575 119.2 250.0 29.8 
Flow through 0.663 ND 1,921.0 ND 
Elution peak 1 0.844 548.8 54.0 29.6 
Elution peak 2 0.070 1.3 50.0 0.064 
Strip 0.011 0.3 20.0 0.007 
Yields 99.4% 
ND: not determined 
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5.3.16 Determination of molecular mass of AH16 using Q-TOF 
MS 
 
The average molecular mass of AH16 was analyzed by Q-TOF 
mass spectrometer. In general, protein appears in multiple charge 
states in mass spectrometry, +40~+66 multi-charged mass ions 
were observed in total ion chromatogram (TIC) of AH16 (Fig. 5-16). 
The multiple charged ions were deconvoluted using MaxEnt to 
determine a molecular weight of AH16. 
 
Mass ions having from +43 to +74 charges were analyzed by 
deconvolution  using MaxEnt (maximum entropy) analysis tool 
(MaxEnt Solutions Ltd, UK) (Ferrige et al., 1991), and the expected 
molecular structure was predicted and the molecular weight of 
AH16 was calculated (Fig. 5-17). The molecular weight of AH16 
was estimated as 148,408.92~148,921.42 Da, and it was about 
2,535.20~3,047.70 Da larger than that of the predicted molecular 
weight (145,873.72 Da). And the difference seemed to be attributed 
to glycosylation of AH16. 
 
Deconvolution of a multiple-charged mass spectrum confirmed 
the molecular weight of AH16 is 148,408.92 ~ 148,921.42 Da (Fig. 5-
17). Major structure of AH16 protein was “glycosylation G0F N(2)-
Lysine C-term (2)” (two glycosylated sites lacking galactose, called 









Fig. 5-16. Total ion chromatogram of AH16. Molecular weight 










Fig. 5-17. Total mass deconvolution analysis of AH16. 
 
 
5.3.17 Amino acids composition analysis of AH16  
 
Amino acid composition analysis was performed and composition 
ratios of most amino acids were similar to theoretical values (Table 
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5-16). However, the composition ratio of tyrosine was less than the 
expected value due to oxidation during acid hydrolysis, and 
recovery yield of other amino acids were more than 90% and very 
similar to theoretical value.  
 
 








Ala  72 72 100.0  
Asx* 108 108.3 100.3  
Glx* 124 124.3 100.2  
Gly 84 84.1 100.1  
Leu 98 97.1 99.1  
Lys 92 90.6 98.5  
Pro 94 93.6 99.6  
Phe 46 45.6 99.1  
Thr  110 109 99.1  
Ile 28 27.7 98.9  
Val 122 120.1 98.4  
His 28 27.2 97.1  
Ser 162 157.3 97.1  
Arg 40 38.7 96.8  
Met 8 7.3 91.3  
Tyr 60 49.3 82.2  
- Asx*: sum of Asn and Asp. - Glx*: sum of Gln and Glu. 
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5.3.18 N-Glycosylation structure analysis of AH16 using NP-
HPLC  
 
By results of identification of N-glycosylation sugar chain structure 
at Asn297 site of AH16 heavy chain, there are approximately 12 
different peaks in the retention time range of 60~100 min. And N-
glycosylation sugar chain structure was analyzed by comparing 
glucose unit (GU) value corresponding retention time of each peak 
(Fig. 5-18). N-glycosylation sugar chain structure at Asn297 of 
AH16 had 99% more bi-antennary sugar chain structure, and was 
predicted to have 62.6% fucosylated form (G0F) lacking galactose 
(Tab. 5-17), and the main peak was observed at retention time of 
72.455 min.  
 
It was predicted that the structures attached one galactose (G1F), 
and two galactose resides (G2F) were 26.4% and 3.91%, respectively. 
The fucosylated form of N-glycosylation sugar chain of AH16 was 

















Fig. 5-18. N-glycosylation profiles of AH16. 
 
 Sialic acid,  Galactose,  N-acetylglucosamine, 
 Mannose,  Fucose 
(After labeling with 2-aminobenzamide fluorescent dye derivatives, N-
glycosylation of AH16 was analyzed using normal phase (NP) HPLC. The 
resulting 12 peaks were assigned glucose unit (GU) values by comparison 
with a 2-aminobenzamide (AB)-labelled dextran ladder (glucose 
homopolymer) (Routier et al. 1998; Melmer et al., 2010). The N-glycan of 




Table 5-17. N-glycosylation pattern and ratio of AH16.  
 
% FG0  FG1  FG2  
Sialylated  
type   
High-mannose  
type   
Fucosylated  
type 
AH16  62.6 26.4 3.91 1.76 0.88 93.5 
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5.3.19 Physico-chemical properties : c-IEF analysis of AH16  
 
The isomer heterogeneity and pI value of AH16 were measured. 
The pI value was in the range of 8.0~9.0, and 10 different isomers 
(isoform 1~10) were observed with a major peak at pI 8.60 (Fig. 5-
19). There were approximately 2 basic (pI 8.68~8.72) and 7 acidic 
forms (pI 8.28~8.52) of AH16 observed. The isomers are related to 










Fig. 5-19. c-IEF profile of AH16. 
Peak 1, pI marker 10.0; Peak 2 ~ 11, AH16; Peak 12, pI marker 7.0 
 
 
5.3.20 Purity analysis : SDS-PAGE of AH16 
 
The purity and molecular weight of AH16 were determined using 
SDS-PAGE under reducing and non-reducing conditions. The main 
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peak was observed in the proximity of the intact 160 kDa IgG form 
under non-reducing conditions, and the heavy chain and light 
chain were identified as 50~60 kDa and 20~30 kDa under reducing 
conditions, respectively (Fig. 5-20). 
Minor bands (shown in Fig. 5-20 A, B, C) were originated from the 
whole IgG and generated by the separation of heavy chain and 
light chain under denaturing conditions in SDS-PAGE analysis, but 













Fig. 5-20. Purity analysis: SDS-PAGE of AH16. 
Lane 1, 6: Standard molecular weight marker 
Lane 2, 7: AH16 (standard); Lane 3, 8: AH16 DS batch 1 
Lane 4, 9: AH16 DS batch 2; Lane 5, 10: AH16 DS batch 3 
A, 2HC + 1 LC; B, 1HC + 1 LC; C, LC 
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5.3.21 Specifications and Analytical Procedures of AH16 for 
quality control 
 
Based on several experimental results, 12 different test items of 
AH16 standards API for quality control, their criteria (Table 5-18), 
and structural, physico-chemical, biological and immunological 




Table 5-18. Results of the Specifications and Analytical Procedures 
for AH16 (DS-16002, 1 batch only). 
 
Test items Acceptance criteria Results 
1. Appearance Colorless and transparent solution Adequate 
2. pH 5.7 ~ 6.7 6.2 
3. Endotoxin < 10.00 EU/mg < 5.92 EU/mg 
4. Identification test 
1) Peptide 
mapping 
Similar chromatogram with the standard N.A.* 
2) cIEF 
1) Position within ± 0.2 standard pI 
2) pI: 8.0 ~ 9.0 
N.A.* 
3) SDS-PAGE 
1) Non-reducing conditions: Position of main band  
is identical to the Standard 
2) Reducing conditions: Positions of Heavy Chain  




5. Purity test 
1) CE-SDS 
1) Non-reducing conditions: LMWI* is 10.0% or less. 
2) Reducing conditions: NGHC** is 2.0% or less. 
1) LMWI: 8.9% 
 
2) NGHC: 1.4% 
2) SE-HPLC 
1) The amount of total impurities: 2.0% or less 
2) The amount of single impurities: 1.0% or less 
1) 0.8% 
2) 0.6%, 0.2% 
3) CEX-HPLC 
1) Acidic form: 55.0% or less 
2) Basic form: 5.0 % or less 
1) 41.8% 
2) 0.0% 
4) HCP 100.0 ppm or less 14.7 ppm 
5) HCD 0.20 ppm or less 0.12 ppm 
6. Contents 1.00 ~ 5.00 mg/ml  2.75 mg/ml 
7. Potency test (in vitro assay) 
1) NCI-N87 80~125% of the potency marked  N.A.* 
2) BT-474 80~125% of the potency marked N.A.* 
*: Not Available, **: Low Molecular Weight Impurities,  





























(Waters, Xevo TQ-S) 
148,408.92 ~ 148,921.42 Da 
Amino acid 
composition 
UPLC (Waters, ACQUITY)  
- Column (Waters, AccQ-Tag  
Ultra) 





- Protein Sequencer  
(Applied Biosystems, 140C 
Microgradient System) 
- UPLC (Waters, ACQUITY)  
- Column (Waters, BEH300 C18) 
- Q-TOF MS (Waters, Xevo TQ-S) 
1) N-terminal 
- HC: NH3-EVQLVESGGG 
- LC: NH3-DIQMTQSPSS 
2) C-terminal 
- HC: SLSLSPG-COOH 




CD (ChirascanTM CD 
Spectrometer, Applied 
Photophysics Ltd.) 
Contents of β-strand and 




NP- HPLC (Waters, e2695) 









- HPIC (ion chromatography) 
(Thermo scientific, ICS 5000) 
- Column  
(Dionex , Carbopac PA10) 
3 kinds of neutral sugar 
1 kind of amino sugar 





Coulter, PA 800 plus) 
non-glycosylation 








CEX-HPLC (Waters, e2695)  
- Column (Dionex, ProPac  
WCX-10 Analytical) 
C-terminal deformed 
body percentages: 6.4% 
Isoform 
distribution 
c-IEF (Beckman Coulter,  
PA 800 plus) 
pI values of ten isoforms 
are within 8.0 ~ 9.0 ranges 
Aggregation 
SE-HPLC (Waters, e2695)  
- Column (TOSOH, TSK-GEL  
G3000SWXL) 
Monomer contents: 99.2% 
Fragmentation 
CE-SDS PAGE Capillary 
Electrophoresis (Beckman 
Coulter, PA 800 plus) 
6 kinds of heterogeneity 
form. Contents of total low- 







SPR (GE Healthcare,  
BIAcore T200) 
HER2 (KD): 






No cross-reactivity to 
5 kinds of antigens 
(PDGF Rβ, VEGF 
R2/KDR/Flk-1, IGF-IR, 







No cross-reactivity to 
3 kinds of antigens 





Specific to domain IV of 
HER2 extracellular domain 
Biological 
property 
ADCC Cell based assay 40.1% cell lysis at 1 ng/ml 
Binding to 
human 
SPR (GE Healthcare,  
BIAcore T200) 
FcγRIIIa (V type, KD) : 
1.07±0.30 x 10-8 M 
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FcγRIIIa FcγRIIIa (F type, KD) : 
2.24±0.10 x 10-8 M 
Binding to 
human FcRn 
SPR (GE Healthcare,  
BIAcore T200) 
8.51±1.01 x 10-8 M 
Binding to 
human C1q 




(GE Healthcare, Canto) 
BT-474: 17.7 % 





NCI-N87 (IC50): 4.3nM 
BT-474 (IC50): 15.9nM 
SK-BR-3 (IC50): 3.1nM 
MDA-MB-453: 40% 
inhibition at 6.7nM 
MCF-7: no inhibition 
Impurities 
HCD   0.12 ppm 
HCP   14.7 ppm 












5.4 Conclusions  
 
The expression vector for producing AH16 was constructed, and 
the AH16 producing AH16F1-3-14-80-26 clone whose antibody 
growth rate and productivity had been consistently maintained 
during 1~15 passages was finally screened as a stable producer cell 
line.  
One basal media and 3 additives were selected, and the final 
productivity of AH16 using the optimized media mixture was 
approximately 1.3g/L in flask culture.  
The three chromatography steps using Protein A resin column (1st 
step) and two steps of ion-exchange chromatography provided the 
yield of 93.8% and the purity of 99.9%. And non-Protein A-based 
cation-exchange chromatography was used as the first capturing 
step to purify AH16 efficiently separated from the impurities such 
as HCP (host cell protein) and HCD (host cell DNA), and provided 
the yield of 99% and the purity of 97.5%.  
Analysis of physico-chemical, biological and immunological 
characteristics of AH16 verified that it meets the standards set 
based on the “Specifications and Analytical Procedures”.  
 
Through this study, the downstream bioprocess technology 





























6.1 Overall Discussions 
 
The major findings in this study and the significance thereof are 
comprehensively summarized as follows.  
 
Firstly, in terms of results, the variants such as AH06 having 
highly improved anti-cancer activities than the reference antibody 
were successfully generated using CDR random mutagenesis and 
phage display technology. 
 
Secondly, in terms of technologies, upstream antibody 
engineering technologies (mutagenesis, phage display, maturation) 
and downstream bioprocess technologies essential for new 
antibody development were established. 
 
Thirdly, in terms of research strategy, mutagenesis was performed 
on CDRs including residues influencing heavy and light inter-chain 
interactions as well as residues that function as direct antigen 
binding, which is distinctive from the preceding research (Gerstner 
et al., 2002). Another distinctive point is that it was possible to 
reduce enormous size of library constructions and resulting 
resources by using the separate mutagenesis of heavy and light 
CDRs as independent sub-libraries and generating combinatorial 
IgG molecules in CHO cell manufacturing stage, instead of 
mutagenesis of heavy and light CDRs in one scFv library.  
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 Therefore, in this chapter, several issues raised through the 
antibody improvement process will be discussed. 
 
Firstly, Herceptin was chosen as a parental antibody in this 
antibody improvement study for the following reason. Since 
enhancement of functional activity of antibody can be primarily 
achieved by improvement of antibody affinity, this study aimed at 
generating antibody variants improved functional activity through 
the affinity maturation or/and optimization. 
Therefore, to determine anti-tumor activity, anti-proliferative 
activity against 2 types of HER2 positive cancer cells as a primary 
criterion was evaluated in combination of well-established 
antibody engineering methods. Since hu4D5, a commonly used 
anti-cancer drug, still needs to be improved and information of its 
CDR residues is available, it was chosen as a parental antibody in 
this model study. So it was able to monitor enhancement or 
improvement of functional activity compared to the parental 
antibody step by step in the process of antibody affinity maturation 
or optimization. 
 
Secondly, screening of all CDRs is worth considering, although 
the significant improvement was achieved from only CDR-H3 
screening. 
To increase probability of isolating the antibody enhanced in 
functional biological activity, this study used both random 
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degenerate PCR method targeting specific residues of CDR-H3, L3 
and L2 and error-prone PCR method targeting variable regions of 
the antibody. For the purpose of enhancing functional biological 
activity of antibody, through setting hu4D5 as a model antibody, 
the isolated AH06 was screened from the library LN02. However, 
since AH06 was screened from the “initial” library LN02, “laterally 
performed or screened” library LN04 and LN05 seems to be 
ineffective to isolate variants more improved.  
However, it was worth attempting in terms of exploring all the 
possibilities to improve the efficacy of antibody as the most 
fundamental purpose of antibody engineering. Since the 
composition of CDR residues varies in different antibodies and is 
an important factor in determining antigen specificity and binding 
affinity, various optimization strategies and protocols can be 
considered.  
Therefore, the conclusion of this study changing parent hu4D5 
using a variety of methods is that CDR-H3 of parent hu4D5 has 
more potential to improve functional efficacy and binding affinity 
to HER2 than the other CDRs, as a result of which this study could 
identify AH06 as a “better variant sequence”.  
 
Thirdly, the orientation of VL and VH of the scFv format could 
make a considerable difference in antibody affinity and activity.  
In this study, the scFv antibody format with VL-linker-VH was 
used to isolate variants improved efficacy. There are reports 
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showing that expression levels in E. coli and binding affinity of the 
scFv having VL-linker-VH orientation is slightly more decreased 
than those of scFv having VH-linker-VL orientation (Weatherill et al., 
2012), on the contrary, it was also reported that the binding activity 
of scFv having VL-linker-VH orientation is more superior to that of 
scFv having VH-linker-VL orientation (Desplanco et al., 1994).  
Therefore, according to the first point that the binding affinity 
which acts as a selection pressure in panning process can be 
influenced by the orientation of VL and VH of the scFv format, and 
also different from various antibodies, and the second point that 
binding capacities (not affinities) of two scFv format generated 
from hu4D5 were not largely different (when two format were 
compared as a preliminary data, data not shown), therefore the 
scFv format having VL-linker-VH orientation was used.  
 
Fourthly, the antibody has differential anti-proliferative activity 
against cancer cell lines, which might affect screening outcomes. 
Since Herceptin has been widely and mainly used in breast cancer 
treatment, the anti-cancer proliferative activity of the antibody 
variants in breast cancer cell line SK-BR-3 first, and then in gastric 
cancer cell line NCI-N87 was screened and evaluated. However, it 
would have been possible to get better clones, if the antibody 
variants had been screened in NCI-N87 first or co-screened in NCI-
N87 and SK-BR-3 cells.  
Although AH06 with the strongest binding affinity showed the 
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most effective anti-proliferative activity, the data (Table 3-4) did not 
show a direct correlation between antigen binding affinity of 
antibody and its biological activity. However, it is consistent with 
the report that the anti-proliferative activity of humAb4D5 variants 
against HER2 overexpressing SK-BR-3 cells is not simply correlated 
with their binding affinity for the HER2 (Carter et al., 1992): the 
variant humAb4D5-3 with a binding affinity similar to that of 
humAb4D5-2 had a significantly enhanced anti-proliferative 






AH06 shows the possibility of a therapeutic antibody. 
 
AH06 showed a 7.2-fold enhanced anti-proliferative activity 
against NCI-N87 gastric cancer cells compared to hu4D5, although 
it did not greatly enhance the activity against SK-BR-3 breast cancer 
cells (Table 3-4). HER2 gene amplification is higher in NCI-N87 
compared with SK-BR-3: the HER2 amplification ratios relative to 
CEP17 (chromosome 17 centromere) were 8.4 and 4.9 in NCI-N87 
and SK-BR-3 cells, respectively (Kim et al., 2008), and 
receptor/ligand avidity generally increases with the density of the 
receptor on cell surface (Lesley et al., 2000). Therefore, AH06 may 
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be able to more efficiently bind to and inhibit NCI-N87 cells having 
a higher density of HER2 than SK-BR-3 cells. 
In addition, its anti-cancer activity of AH06 was HER2-sepcific 
and its effect was confirmed at the level of signal transduction as 
well, indicating that AH06 is distinctly superior to hu4D5. 
Therefore, it is able to suggest that AH06 could be clinically 
developed as a therapeutic anti-cancer antibody over hu4D5 
(Herceptin). 
 
Panning strategy using “one pot phage mixture of sublibraries” 
increased the chance to screen the improved variants compared to 
that using “each phage library” 
Library LN01 and LN02 were randomized at positions of 4 
residues and 6 residues, respectively; LN03 was randomized as 2 
sub-libraries at different positions of 4 residues and 4 residues, 
respectively. Since both LN01 and LN02 were derived from CDR-
H3 library after generating each phage library of LN01 and LN02 
from each constructed DNA library, they were mixed into “one-
pot” to perform the panning process. Since both sub-libraries of 
LN03 were derived from CDR-L3 library, they were mixed in the 
same manner. 
The reason why two phage libraries were mixed into “one-pot 
mixture” and screened in this manner was that it was more efficient 
in order to save labor, time and resources than the separate 
screening with each library. As a result, AH06 was screened and 
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isolated from LN01 and LN02 phage library mixture, suggesting 
that it was the economic screening as intended. It might be the 
same for LN03, although variants isolated from LN03 did not 
improve functional activity.     
The “one-pot mixture” strategy mentioned in Overall Discussion 
section, if the number of randomizing residues of specific CDR is 
over 7~8, it is more efficient to make and screen sub-libraries with 
randomized each 6 residues rather than to randomize the whole 
residues of those CDRs at a time. Thus, in such a case, after the 
phage libraries are randomized and expressed in E. coli host, the 
“one-pot mixture” strategy would be preferable.  
However, such a “one-pot mixture” strategy would have some 
limitations and disadvantages as follows. If “undesirable clones” 
are more amplified due to higher expression level during the phage 
amplification stage in E. coli host although their binding affinities 
are not superior to “desirable clones”, they could be enriched and 
survived in the course of screening.  
Consequently, there is a possibility that “desirable clones” are 
eventually “naturally-selected” to diminish. In other words, if 
“one-pot mixture” of phage sub-libraries from the same CDRs is 
screened, “loss or wash-out of a better candidate” could be one of 
possible disadvantages or limitations. 
As shown here, functional activity of antibodies can be sufficiently 
improved using the methods such as random mutagenesis using 
degenerate and error-prone PCR and site-directed mutagenesis at 
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specific positions of CDRs and variable region. However, since it is 
practically difficult to randomize and screen all the CDR regions or 
residues, it is necessary to decide randomizing target CDRs and 
number of residues. 
If there were many residues and CDRs as CDR-H2 to randomize, 
it is appropriate to make several sub-libraries with a unit of 6 
randomized residues for convenient library construction and “full 
and thorough and without any loss” screening. Since the study 
could not help considering saving research resources such as cost 
and labor, and also time which takes about 20~30 days from library 
construction, several panning protocols, selection of positive clones 
to novel sequence identification, it would be more proper approach 
using “one-pot mixture” strategy. 
In order to generate randomized libraries in an efficient and 
productive way, several factors such as labor, time, resources and 
feasibility should be considered, and particularly the number of 
CDR residues is a one of most important factors.  
To increase the possibility to select variants which has much more 
anticancer activity, in this study, variants were generated step-by-
step through the random degenerate mutagenesis PCR with some 
positions in CDR-H3, CDR-L3, and CDR-L2, respectively, as well as 
random error-prone mutagenesis PCR with 2~4 sections of a whole 
area of variable region. Random degenerate mutagenesis on CDR-
H2 that is generally important in antigen-binding and specificity of 
antibodies was not carried out in this study. As mentioned in 
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Chapter 3.1 Results, the reason not to randomize CDR-H2 will be 
described below in detail. 
In case of hu4D5 as a model in this study, it has been known that 
the rest of residues except of 3 exposed residues (50, 56, and 58) of 
the position 50~65 in CDR-H2 were located inside the variant and 
did not directly interact with antigen HER2 (Gerstner et al., 2002). 
Therefore, if the rest residues except for those three residues and 
CDR-H2 key residue R50 that can significant influence the binding 
affinity and stability of the antibody were exclude from 
randomization target positions, in actually, it was only able to 
randomize positions CDR-H2 Y56, R58 and evaluate the influence 
for binding affinity without some difficulties.  
However, since the results from randomization at positions CDR-
H2 Y56 and R58 revealed that the frequencies that appeared as 
variant residues changed to not original residues but the other 
different residues were less than 40%, although if those two 
positions were randomized, it might be practically less effective in 
residue substitution, we cannot randomize those two positions.  
In general, since substitution of antibody variable domain 
sequences can influence interactions between not only "exposed 
residues" and its specific antigen, but also antibody internal heavy 
and light chain, and the resulting structural stability of the 
antibody can be influenced from such changes, and so, the 
antibody-antigen binding strength can be changed. Therefore, not 
only "those exposed residues" involved direct binding to its antigen, 
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but also "those residues" influencing heavy and light inter-chain 
interactions (Hawkins et. al, 1993; Chatellier et. al, 1996; Carter et. al, 
1992; Schier et. al, 1996; Vajdos et al., 2002) can be randomized as 
target residues. 
In fact, since it is difficult to elucidate what residues act at which 
position in the situation that there is no modeling analysis data for 
antibody-antigen binding mode, nor being studied, randomization 
of all positions in CDR could be the most acceptable strategy for 
antibody optimization. Therefore, no matter what residues 
sequences and length of CDRs are, it is necessary to use or adopt 
productive randomization libraries construction and screening 
strategies satisfactory in terms of labor, time, resources, easiness 
and positive outcomes.  
However, by the need and possibilities, if this study surely try to 
randomize 17 residues of CDR-H2, though it was able to omit key 
residue R50 of CDR-H2 from target residues, the number of 
remaining target residues for randomization is as many as 16. And 
if this study construct two sub-libraries sequentially randomizing 8 
residues and 8 residues, since two theoretical library sizes are 5.12 x 
1010, respectively, it is necessary to use a huge or enormous costs 
and times, which means that constructing libraries is practically 
impossible to do.  
Alternatively, if this study construct three sub-libraries 
sequentially randomizing 6 residues, 6 residues and 4 residues, 
three theoretical library sizes are 6.4 x 107, 6.4 x 107 and 1.6 x 105, 
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respectively. Thus, constructing three sub-libraries is relatively 
much easier, but in this case, the study must compare or monitor 
the screening results and try to do in various combinations. And 
finally, it was unable to construct libraries for CDR-H2 
randomization.  
 
For randomization of CDR having more than 10 resides, the most 
efficient way would be the use of sublibraries: randomization of 
each 5~6 residues and subsequent mixing of the sublibraries in one-
pot.  
Nevertheless, if there are many residues consisting of interesting 
CDRs and randomization is necessary to improve or increase 
affinity maturation or functional activity, it is able to construct and 
screen randomized library using sublibraries consisting of 5~6 
randomized residues. For example, about 10 “best-binding 
variants” selected from each library is used at a template for the 
next step library construction. Thirty~fourty variant DNA extracted 
from the best-binding variants in the 3~4 libraries is mixed in one-
pot and then combinatorial library of best-variants is constructed 
with ease, and further screening (panning) is performed. By using 
these methods or strategies, it is supposed that it is able to obtain 
improved variants more easily.  
The purpose of this study is to examine whether the therapeutic 
efficacy of the antibody can be improved through antibody 
engineering methods. This study used hu4D5 (Herceptin) as a 
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model study case, since it has potent anti-cancer activity and high 
binding affinity (KD in sub-picomolar range).  
Herceptin is well known antibody, and its sequences are already 
known. Nevertheless, it is still an attractive model to investigate 
what kinds of random mutagenesis strategies can be used for 
improvement of binding affinity and functional efficacy, and how 
much improvement can be achieved from the result. 
In addition, this study could suggest basic and simple solutions or 
applications on how to use of previously available known 
information for antibody optimization process and how to establish 
an optimization strategy without any information such as key 
residues and important positions of antibody-antigen interaction. 
If the information is not available, in generally, it is able to get the 
information for key residues and important positions of CDR 
regions through analyzing and comparing the results of functional 
activities and binding affinities (KD) from alanine scanning 
mutagenesis.  
Therefore, based on the information, it is able to construct and 
screen libraries randomized at any positions except key and other 
important residues. This model case study could establish the 
overall protocol and strategy for the purpose of improving 
functional activity of the antibody, which can be applicable to any 
other antibody optimization study.  
 
In this study, although it was unable to randomize all the CDRs of 
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the parent antibody hu4D5 due to research limitation factors such 
as resources, labor and time, to isolate the improved variants, this 
study randomized some of CDR residues generally known to be 
important for functional activity and binding affinity of the 
antibody using various methods and strategies. As a result, this 
study generated the variant AH06 whose binding affinity as well as 
functional activity is better than those of parent antibody hu4D5, 
which is very important achievement and meanings.  
AH06 showed approximately 7.0-fold enhanced anti-proliferative 
activity against NCI-N87 gastric cancer cells compared to hu4D5, 
although it did not greatly enhance the activity against SK-BR-3 
breast cancer cells. In addition, its anti-cancer activity was HER2-
sepcific and its effect was confirmed at the level of signal 
transduction as well, indicating that AH06 is distinctly superior to 
hu4D5. Therefore, this study suggest that AH06 could be clinically 
developed as a therapeutic anti-cancer antibody over hu4D5 
(Herceptin). 
 
In addition, this study was not designed for elucidating novel 
biological principles, phenomena, and signaling mechanisms or 
discovering new biomolecules or developing analysis methodology, 
but it is a planned model study to show how to design strategies or 
methods to improve functionality and efficacy of antibodies that 
are currently used for therapeutics and diagnostics in the clinical 
practice. This study was also performed to test if the strategies and 
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methods confirmed from this model study could be applied to 
enhance functionality of other therapeutic antibodies.  
By excluding key and other relatively conserved residues from 
randomization, as this methodology or strategy is general and 
widely adopted, it was able to reduce the library size and thus save 
labor, time and related resources for screening.  
As this study, it can sufficiently improve functional activities of 
antibodies with methods for random mutagenesis using degenerate 
and error-prone PCR and for site-directed mutagenesis at specific 
positions of CDRs and variable region. However, since it is 
impossible to randomize and screen all the CDR regions or residues, 
it is necessary to decide randomizing target CDRs and number of 
residues. 
For this reason, in this study, CDR-H3, L3 and L2 were selected as 
target CDRs to randomize and screen. In addition, although AH06 
isolated from this study is an improved antibody variant, it is 
unable to conclude that AH06 is ultimately the best antibody 
derivable from parent hu4D5 and so there is no possibility of 
getting more improved antibody than AH06. That is, it is possible 
to be selected or generated as many as better variants than AH06 
by the order and combinations of residues far different from those 
of AH06.   
Since it is impossible to construct and screen libraries by 
randomizing residues in all the possible and theoretical 
combinations in the antibody optimization process, it is extremely 
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important to set the quantitative selection criteria which are well 
describing and properly representing the purpose of antibody 
optimization such as improvement of functional activity, binding 
affinity, specificity, effector function, productivity, stability and 
reduction of immunogenicity.   
Therefore, in the study for antibody optimization process, it is 
economical and important to make Go or No-Go decision step-by-
step by monitoring if variants meet quality standards at each 
screening step. It means that the antibody optimization process is a 
step to select the variants that meet the requirements among 
numerous variants. 
 
In summary, the CDR mutagenesis and the combinatorial library 
expression strategies can be used for optimizing and developing a 
new antibody as the effective methodology, and thus is more 
significant than the outcomes in terms of experimental results and 
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항 HER2 항체 hu4D5 (Trastuzumab, Herceptin) 보다 치료활성
이 향상된 biobetter 를 도출하고, 항체 최적화 기술을 응용하기 
위한 하나의 모델로서 hu4D5 를 이용하였다. hu4D5 의 CDR-H3, 
L3 및 L2의 몇몇 위치에 대하여 무작위 돌연변이를 유도한 scFv 
라이브러리를 구축하고, 파아지 디스플레이를 이용한 가혹 조건
에서 선별하는 방법을 통하여 유방암 세포 에 대한 세포증식저해
활성을 일차적 선정 기준으로 스크리닝하였다.  
139종의 변이체중에서, AH06 이 hu4D5 에 비하여 위암 세포에 
대한 세포증식저해활성 (IC50: 0.81 nM)과 HER2에 대한 친화도 
(KD: 60 pM)가 각각 7.2-fold 및 7.4-fold로 향상되는 등, 가장 
우수한 효능을 나타내었다.  
AH06 항체는 HER2 도메인 IV에 특이적으로 결합하며, HER2 이
외의 다른 수용체에는 교차 반응성을 가지고 있지 않았으며 위암 
세포 NCI-N87에서 인산화-HER2와 인산화-AKT 수준을 hu4D5 와 유
사한 수준으로 억제하지만, 하위 신호전달에서 p27 수준은 좀더 
많이 증가시켰다.  
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결합 에너지 계산 결과, AH06 의 CDR-H3의 W98, F100c, A101, 
L102로의 아미노산 잔기 변화가 HER2에 대한 결합을 안정화시키
는 것으로 나타났다. 분자 모델링으로 시뮬레이션한 결과, AH06 
내의 W98 의 aromatic ring 과 항원 HER2 도메인 IV 내의 I613 
의 aliphatic group 사이에 직접적인 소수성 상호작용 및 CDR-H3 
F100c 의 phenyl ring 과 VL 의 Y36, P44 및 F98 로 구성된 소수
성 치환기 사이의 사슬간 소수성 상호작용들의 상승효과에 의하
여 HER2에 대한 친화도가 향상된 것으로 추론되었다. 
AH16 항체 발현 벡터를 제조하였고, 15 계대까지 발현량과 세
포성장속도가 일정하게 유지되는 AH16F1-3-14-80-26 clone을 최
종 생산세포주 (stable cell line)으로 선별하였다. 1종의 기본 
배지와 3종의 첨가물을 선정하였고, 이의 최적 조합 배지를 이용
한 최종 생산성은 플라스크 상에서 약 1.3g/L 이었다.  
1차 Protein A 레진 과 2단계의 이온교환 크로마토그래피 등 3
단계의 순차적 정제를 통하여 수율 93.8%, 순도 99.9% 의 공정을 
하였고, non-Protein A 공정으로서 양이온 교환 크로마토그래피
를 이용하여 HCP (host cell protein), HCD (host cell DNA) 같
은 불순물을 효과적으로 분리 할 수 있었으며, 수율은 99%, 순도
는 97.5% 였다.  
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AH16 원료의약품 (API: active pharmaceutical ingredients) 
의 구조, 물리 화학적 특성, 면역학적, 생물학적 특성을 분석한 
결과, AH16 API는 자체적으로 설정한 “기준 및 시험법” 항목에 
부합되었다. 
본 연구를 통하여 다양한 치료용 선도 항체의 효능 개량에 필
요한 upstream 항체공학 기술과 항체 생산에 필요한 downstream 
바이오공정 기술을 확립, 응용하였다. 
 
 
주제어: 항체공학, 항체 최적화, HER2, 파아지 디스플레이, 
무작위 돌연변이, 세포증식 저해활성, 결합 친화도, Herceptin, 
바이오공정 개발, 생산세포주, 배양 공정, 정제 공정  
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